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INTRODUCTION 
Many techniques are being employed for the solubility enhancement of poorly 
soluble drugs to resolve the bioavailability issue due to inadequate dissolution rate. 
Various approaches make use of hydrophilic polymers as solubility enhancers acting 
through a variety of mechanisms such as amorphization, co-solvency, micelle formation 
or inclusion complexes. These techniques impart many advantageous effects in the 
formulation development. But usually these approaches show lack of stability and 
decreasing success rate over a period of storage. One of the remarkable demerits of 
solid dispersions, glass solutions, eutectic mixtures and inclusion complexes is 
formation of sticky and hygroscopic mass resulting in the poor flow characteristics]. Due 
to this set-back, industrial feasibility of the final dosage form becomes very difficult. The 
liquisolid technology emerged as a new drug delivery system distinguished by its 
characteristics and ability to deliver variety of drugs. Liquisolid drug delivery system has 
gained attention of pharmaceutical researchers due to its contribution in the solubility 
enhancement as well as dissolution retarding approaches depending on the need and 
design of the formulation. With the liquisolid technology as described and patented by 
Spireas, a liquid may be transformed into a free flowing, readily compressible and 
apparently dry powder by simple physical blending with selected excipients. Three 
major components in the formulation of liquisolid compacts are liquid medication, carrier 
and coat material. Other excipients such as use of disintegrant or release retarding 
polymers for modification of release profile are used as per the objective and need of 
the formulation. The first component i.e. liquid medication can either be a liquid drug, a 
drug suspension or a drug solution in suitable non-volatile liquid vehicles. Inert, 
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preferably water-miscible organic solvent systems with high boiling point such as 
propylene glycol, liquid polyethylene glycols or glycerin are best suitable as „liquid 
vehicle‟. The solubilization of the drug in a non-volatile solvent keeps the drug in 
uniformly and molecularly dispersed form. This creates opportunity to enhance the drug 
release. The liquid medication is incorporated into the second component of the system 
i.e. the porous carrier material. Once the carrier is saturated with liquid, a liquid layer is 
formed on the particle surface which is instantly adsorbed by the third component i.e. 
coat materials. Thus, an apparently dry, free flowing and compressible powder is 
obtained. Usually, microcrystalline cellulose is used as carrier material.The third 
component i.e. coat material avoids the re-aggregation of the liquisolid particles and 
imparts higher flow characteristics. The coating also assists the drylooking character of 
the system. Many times, amorphous silicon dioxide (colloidal silica) is used as coating 
material.. Liquisolid formulation containing a drug solution or drug suspension of poorly 
soluble drugs in a solubilizing vehicle shows enhanced drug release due to increased 
surface area of drug available for release, increased aqueous solubility of the drug by 
co-solvency and improved wettability of the drug particles.Accordingly, this improved 
drug release may result in a higher drug absorption in the gastrointestinal tract and thus, 
an improved oral bioavailability 
HISTORICAL DEVELOPMENT: 
 Liquisolid technology is the next generation of “powdered solutions” an older 
technique which was based on the conversion of a solution of a drug in a nonvolatile 
solvent into a dry-looking, non-adherent powder by mainly adsorbing the liquid onto 
silica having large specific surfaces. However, such preparations have been studied for 
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their dissolution profiles while being in a powder dispersion form and not as compressed 
entities, simply because they could not be compressed into tablets. In later 
developments on powdered solutions, compression enhancers and binders such as 
microcrystalline cellulose were incorporated in such systems to improve the 
compactability of the blend. In these investigations, however, large quantities of silica 
were being used and the flow as well as compression properties of the product were 
never validated and optimized to the industrial specifications and requirements. 
Specifically, when such modified powdered solutions were compressed into tablets, 
they showed significant problems of “liquid squeezing out” and unacceptably soft 
tablets. Thus the industrial application of such systems was hindered. Liquisolid 
compacts, on the contrary, show acceptable flow and compressibility and deserve 
industrial application. In addition, the term “liquid medication” does not only imply drug 
solutions, as in powdered solutions, but also drug suspensions, emulsions or liquid oily 
drugs. Therefore, in contrast to “powdered solutions”, the term “Liquisolid compacts” is 
wider and more general and it may encompass four different formulation systems viz. 
powdered drug solutions, powdered drug suspensions, powdered drug emulsions and 
powdered liquid drugs. Furthermore, the earlier term “powdered solution” seems to be 
inadequate even in describing the original systems, since it has not been proven that 
the drug remains in  solution in the liquid vehicle after its deposition on the extremely 
large powder surface of silica used. 
PHARMACEUTICAL APPROACHES TO ENHANCE THE DISSOLUTION OF DRUGS: 
1. Micronization: In which particle size of solid drug is reduced to 1to 10µ by spray 
drying or fluid energy mill example: sulpha drugs. 
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2. Use of surfactants: surface active agents enhance the dissolution rate by 
promoting wetting and penetration of dissolution fluid into solid drug particles 
example steroids like spironolactone. 
3. Use of salt forms: salts have improved solubility and dissolution characteristics 
in comparison to the original drug. Example salt of basic drug like Atropine is 
more soluble than the parent drug. 
4. Alteration of pH of the Drug Microenvironment: achieved in two ways in situ 
salt formation and the addition of buffers to the formulation e.g. buffered aspirin 
tablets. 
5. Use of metastable polymorphs: Metastable polymorphs are more soluble than 
the stable polymorphs of drug that exhibits polymorphism, e.g. chloramphenicol 
palmitate. 
6. Solute –solvent complexation: solvates of drugs with organic solvents 
generally have higher aqueous solubility than the original drug, e.g. 1:2 
griseofulvin benzene solvate. 
7. Solvent deposition: In this method poorly aqueous soluble drug is dissolved in 
organic solvent and deposited on an inert hydrophilic, solid matrix, e.g. nifedipine 
is dissolved in alcohol and deposited in starch by evaporation of solvent. 
8. Selective adsorption on insoluble carriers: A highly active adsorbent can 
enhance the dissolution rate, e.g. bentonite. 
9. Solid solution-  Use of solid solution: solid solution is a binary system 
comprising of solid solute molecularly dispersed in a solid solvent. Use of 
eutectic mixtures: These systems are also prepared by fusion method it is slightly 
   CHAPTER I                                                                                                INTRODUCTION 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI-20  5 
 
differ from solid solution in that fused melt of solute –solvent show complete 
miscibility but negligible solid – solid solubility.  The use of solid dispersion: 
These are generally prepared by solvent or co precipitation method where both 
guest solute and the solid carrier solvent are dissolved in common volatile liquid 
such as alcohol. The liquid removed by evaporation under reduced pressure or 
by freeze drying which result in amorphous precipitation of guest in crystalline 
carrier. 
10. Molecular encapsulation with Cyclodextrins: The beta and gamma 
Cyclodextrins and several of their derivatives are unique in having the ability to 
form molecular inclusion with hydrophobic drugs having a poor aqueous 
solubility. These cyclodextrin molecules are versatile in having a hydrophobic 
cavity of a size suitable enough to accommodate hydrophilic drug as a guest; the 
outside of the host molecule is relatively hydrophilic. Thus the molecularly 
encapsulated drug has greatly improved aqueous solubility and dissolution rate. 
However, among them, the technique of Liquisolid compacts” is one of the most 
promising techniques. Low cost, simple formulation technique and capability of 
industrial production serve to be the advantages of this technique.:   
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CONCEPT OF LIQUISOLID SYSTEM 
FIG-1:Theoretical concept of liquisolid system  
 
 
                                               
 
 
 
 
 
] 
 
 
When the drug dissolved in the liquid vehicle is incorporated into a carrier 
material which has a porous surface and closely matted fibers in its interior such as 
celluloses, both absorption and adsorption take place. The liquid initially absorbed in the 
interior of the particles is captured by its internal structure. After the saturation of this 
process, adsorption of the liquid onto the internal and external surfaces of the porous 
carrier particles occurs. Then, the coating material having high adsorptive properties 
and large specific surface area provides the liquisolid system the desirable flow 
characteristics .In liquisolid systems, the drug is already in solution form in liquid 
vehicle, while at the same time, it is carried by powder. The wettability of the compacts 
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in the dissolution media is one of the proposed mechanisms for explaining the 
enhanced dissolution rate from the liquisolid compacts. Non-volatile solvent present in 
the liquisolid system facilitates wetting of drug particles by decreasing interfacial tension 
between dissolution medium and tablet surface. Thus, due to substantial increase in 
wettability and effective surface area for dissolution, liquisolid compacts may be 
expected to reveal enhanced release profiles of water-insoluble drugs. Since dissolution 
of a non-polar drug is often the rate limiting step in gastrointestinal absorption, better 
bioavailability of an orally administered water-insoluble drug is achieved when the drug 
is already in solution, thereby displaying enhanced dissolution rates. However, the drug 
release profile entirely depends on the characteristics of drug, carrier and vehicle used. 
Thus by altering these variables, liquisolid technique can be used for enhancing or 
retarding the drug release. 
CLASSIFICATION OF LIQUISOLID SYSTEMS: 
A. Based on the Type of liquid Medication: Based on type of liquid medication 
used in the formulation, liquisolid systems may be classified into four subgroups:  
1. Powdered drug solutions 
2. Powdered drug suspensions 
3. Powdered drug emulsions 
4. Powdered liquid drugs 
The first three may be produced from the conversion of drug solutions or drug 
suspensions and emulsions, the later from the formulation of liquid drugs into liquisolid 
systems. Since non-volatile solvents are used to prepare the drug solution or 
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suspension, the liquid vehicle does not evaporate and thus, the drug carried within the 
liquid system, remains dispersed throughout the final product. B. Based on the 
Formulation Technique: Depending on the technique used, liquisolid systems may be 
classified into two categories: 
1. Liquisolid compacts 
2. Liquisolid microsystems 
Liquisolid compacts are prepared using the previously outlined method to produce 
tablets or capsules, whereas the liquisolid microsystems are based on a new concept 
which employs similar methodology combined with the inclusion of an additive e.g. PVP, 
in the liquid medication which is incorporated into the carrier and coating materials to 
produce an acceptably flowing admixture for encapsulation. The advantage stemming 
from this new technique is that the resulting unit size of liquisolid microsystems may be 
as much as five times less than that of liquisolid compacts 
MATHEMATICAL MODEL TO DESIGN LIQUISOLID SYSTEM: 
The flowability and compressibility of liquisolid compacts are addressed 
simultaneously in the “new formulation mathematical model of liquisolid systems”. The 
model can be employed to compute the appropriate quantities of the carrier and coating 
materials required to produce acceptably flowing and compressible powders. The 
calculation of composition of carrier, coat and liquid medication is based on new 
fundamental powder properties called as “flowable liquid retention potential” (Φ- value) 
and “compressible liquid retention potential”(Ψ-number) of the constituent powder.  
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The flowable liquid retention potential (Φ-value) of a powder is defined as the 
maximum amount of a given non-volatile liquid that can be retained inside its bulk (w/w) 
while maintaining acceptable flowability.  
The compressible liquid retention potential (Ψ-number) of a powder is the 
maximum amount of a given non-volatile liquid, the powder can retain inside its bulk 
(w/w) while maintaining acceptable compactability, to produce compacts of suitable  
hardness and friability, with no “liquid squeezing out” phenomenon during the 
compression process.  
The Φ-value of powders may be determined using the liquisolid flowability test. 
The Ψ-number of powders may be determined by liquisolid compressibility test which 
employs the „plasticity theories‟ to evaluate the compaction properties of liquid/ powder 
admixtures. 
The liquisolid flowability test is basically a titration-like procedure in which 25 to 
30 g of mixture of the powders under investigation, with increasing amounts of a 
nonvolatile solvent (i.e. liquid/solid weight composition) are prepared using a standard 
mixing process. The flow rates and consistencies are assessed using a Recording 
Powder Flow meter. The liquid/solid weight composition (w/w) in that admixture, which 
just complies with a desired and preselected limit of acceptable flowability, is taken as 
the Φ-value of the excipient. The non-volatile solvent used in the liquisolid flowability 
test should be the one selected to be included in the liquid medication (drug solution or 
drug suspension) of the targeted liquisolid product. While the study consisting the use of 
a liquid drug, the liquisolid flowability test should be conducted with the liquid drug itself. 
This value will change when different solvent or solvent system is employed. 
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 According to the theories, the carrier and coating powder materials can retain 
only certain amount of liquid while maintaining acceptable flow and compression 
properties. Hence, the excipient ratio (R) or the carrier: coat ratio of the powder system 
used should be optimized.  
                                              R = Q/q                                                            (1) 
R represents the ratio between the weights of carrier (Q) and coating material (q) 
present in the formulation. 
 An acceptably flowing and compressible liquisolid system  can be prepared only 
if a maximum liquid on the carrier material is not exceeded. Such a characteristic 
amount of liquid is termed as Liquid load factor (Lf), which is defined as the ratio of the 
weight of liquid medication (W) over the weight of the carrier powder (Q) in the system, 
which should be possessed by an acceptably flowing and compressible liquisolid 
system. 
                                                        Lf= W/Q                                                                (2)  
The relationship between the powder excipients ratio (R) and liquid load factor 
(Lf) of the formulations can be given as follows:  
                                                       Lf = Φ + φ (1/R)                                                      (3) 
 Where, Φ and Φ are the Φ-values of carrier and coat material respectively.  
In order to calculate the required ingredient quantities, the flowable liquid 
retention potentials (Φ-values) of powder excipients were utilized based on reported 
values in the literature. As from equation 3, Φ and φ and are constants, R and Lf were 
determined from the linear relationship of Lf versus 1/R to calculate the required 
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weights of the excipients used. Next, according to the used liquid vehicle 
concentration, different weights of the liquid drug solution (W) are used. Thus by 
knowing both Lf and W, the appropriate quantities of carrier (Q) and coating (q) 
powder materials required to convert a given amount of liquid medication (W) into an 
acceptably flowing and compressible liquisolid system could be calculated from  
equation 1 and 2. 
COMPONENTS OF LIQUISOLID SYSTEMS: 
The major formulation components of liquisolid compacts are: 
1. CARRIER MATERIAL  
These are compression-enhancing, relatively large, preferably porous particles 
possessing a sufficient absorption property which contributes in liquid absorption. E.g. 
various grades of cellulose, starch lactose ,sorbitol, Avicel PH 102 and 200 , Eudragit 
RL and RS, amorphous cellulose etc. 
2. COATING MATERIAL  
These are flow-enhancing, very fine (10 nm to 5,000 nm in diameter), highly 
adsorptive  coating particles (e.g., silica of various grades like Cab-O-Sil M5, Aerosil 
200, Syloid  244FP etc.) contributes in covering the wet carrier particles and displaying 
a dry-looking  powder by adsorbing any excess liquid. 
 
3. NON-VOLATILE SOLVENTS 
 Inert, high boiling point, preferably water-miscible and not highly viscous organic 
solvent systems. Various non-volatile solvents used for the formulation of liquisolid 
systems  include Polyethylene glycol 200 and 400, glycerin, polysorbate 80 and 
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propylene glycol, propylene  glycol, liquid polyethylene glycols, polysorbates, glycerin, 
N, N- dimethylacetamide, fixed oils, etc. 
4. DISINTEGRANT  
Superdisintegrants increases the rate of drug release, water solubility and wet 
ability of liquisolid granules. Mostly Superdisintegrants like sodium starch glycolate and 
crosspovidone and croscarmellose sodium. 
        
      
Fig-2: Mechanism of action of superdisintegrants. 
PREPARATION OF LIQUISOLID SYSTEM: 
As shown in figure, a liquid drug can be converted into a dry-looking liquisolid 
system without being further chemically modified. If liquisolid system of a solid water-
insoluble drug is to be formulated, it should be initially dissolved or suspended in a 
suitable non-volatile solvent system to produce a drug solution or drug suspension of 
desired concentration. 
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Next, a certain amount of the prepared drug solution or suspension or a liquid 
drug itself is incorporated into a specific quantity of carrier material which should be 
preferably of a porous nature and possessing sufficient absorption properties. The 
resulting wet mixture is then converted into a dry-looking, non adherent, free-flowing 
and readily compressible powder by the simple addition and mixing of a calculated 
amount of coating material. 
FIG-3: Steps involved  in the preparation of  liquisolid  system 
 
Excipients possessing fine and highly adsorptive particles are suitable for this 
step. Before compression or encapsulation, various adjuvant like lubricants and 
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disintegrants (immediate release) or binders (sustained release) may be added to final 
liquisolid system to produce liquisolid compacts i.e. tablet or capsule. 
MECHANISMS OF ENHANCEMENT OF DRUG RELEASE: 
  Several mechanisms of enhanced drug release have been postulated for 
liquisolid systems. The three main proposed mechanisms include increased surface 
area of drug available for release, increased aqueous solubility of the drug due to 
presence of nonvolatile vehicle and improved wettability of the drug particles due to 
cosolvent effect of the vehicle used. 
A.Increased Effective Surface Area: If the drug within the liquisolid system is 
completely dissolved in the liquid vehicle, it is located in the powder substrate still in a 
solubilized and molecularly dispersed state. Therefore, the surface area of drug 
available for release is much greater than that of drug particles within directly 
compressed tablets. Accordingly, with increasing drug content exceeding the solubility 
limit and thus, increasing fraction of undissolved drug in the liquid vehicle the release 
rate decreases. With various drugs it could be shown that the release rates are directly 
proportional to the fraction of the molecularly dispersed drug (FM) in the liquid 
formulation. FM is defined by Spireas as the ratio between the drug's solubility (Sd) in 
the given liquid vehicle and the actual drug concentration (Cd) in this vehicle carried by 
each system. Therefore,  
                                                     FM =Sd/ Cd                                                               (4) 
 In addition it is thought that the adsorption and absorption of molecularly 
dispersed drug onto the surface and interior of the carrier particles impart increased 
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effective surface area available for the mass transfer during the drug dissolution 
process.  
B.Increased Aqueous Solubility: In addition to the first mechanism of drug 
release enhancement, it is expected that the solubility of the drug might be increased 
with liquisolid systems. In fact, the relatively small amount of liquid vehicle in a liquisolid 
compact is not sufficient to increase the overall solubility of the drug in the aqueous 
medium. However, in the micro-environment of the solid/liquid interface between an 
individual primary liquisolid particle and the release medium, it is possible that the 
amount of liquid vehicle diffusing out of a single liquisolid particle together with the drug 
molecules might be sufficient to increase the aqueous solubility of the drug if the liquid 
vehicle can act as a cosolvent. The overall increase in the solubility of drugs caused by 
liquisolid systems was confirmed in various studies. 
C.Improved Wetting Properties: Due to the fact that the liquid vehicle can 
either act as surface active agent or has a low surface tension, wetting of the primary 
liquisolid particles is improved.                   
Fig-4: Wetting property of liquisolid system. 
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Wettability of these systems can be demonstrated by contact angles and water 
rising times. Also the adsorption of the drug on the carrier particles increases the 
effective surface area, improving the contact of drug and wettability. 
Dissolution studies on liquisolid tablets 
           Tablets should be sufficiently hard to resist breaking during normal handling and 
yet quickly disintegrate properly after swallowing. 
Dissolution rate (DR) is explained according to the “Noyes – Whitney” equation 
and “diffusion layer model” dissolution theories. 
   DR = (D/h) S (Cs- C) 
According to this equation, stagnant diffusion layer thickness is h, and formed by 
the dissolving liquid around the drug particles. D is the diffusion coefficient of the drug 
molecules transported through it, S is the surface area of the drug available for 
dissolution, C is the drug concentration in the bulk of the dissolving medium, and Cs is 
the saturation solution of the drug in the dissolution medium. Dissolution tests for 
liquisolid tablets were done at constant rotational speed and in identical dissolution 
media, thus allowing estimation of the thickness of the stagnant diffusion layer (h). From 
this equation, dissolution rate is directly proportional not only to the concentration 
gradient of the drug in the stagnant diffusion layer (Cs- C), but also to its surface area 
(S) available for dissolution. 
For estimation and comparison, drug dissolution rates (DR) of drug were used, 
with amount of drug dissolved per min presented by each tablet formulation during the 
first 10 minutes. (Shashidher Burra et al., 2011).  
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           (M x D) 
D R = ––––––– 
             1000 
Where, 
M = Total amount of pure drug in each tablet 
D = Percentage of drug dissolved in the first 10 minutes 
ADVANTAGES 
Liquisolid tables have many advantages. These include: 
  Liquisolid systems are low cost formulations than soft gelatine capsules. 
 Drug release can be modified using suitable formulation ingredients 
  Drug can be molecularly dispersed in the formulation. 
  Capability of industrial production is also possible. 
  Enhanced bioavailability can be obtained as compared to conventional tablets. 
  Several slightly and very slightly water-soluble and practically water-insoluble 
liquid and solid drugs can be formulated into liquisolid systems. 
  Even though the drug is in a tablet or capsule form, it is held in a solubilized 
liquid state, which contributes to increased drug wetting properties, thereby 
enhancing drug dissolution. 
  Rapid release liquisolid tablets or capsules of water insoluble drugs exhibit 
enhanced In-vitro and in-vivo drug release when compared to their commercial 
counter parts, including soft gelatin capsules preparation. 
  Sustained release liquisolid tablets or capsules of water insoluble drugs exhibit 
constant dissolution rates (zero-order release) comparable only to expensive 
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Commercial preparations that combine osmotic pump technology and laser-
drilled tablets. 
 Can be applied to formulate liquid medications such as oily liquid drugs. 
  Better availability of an orally administered water insoluble drug.  
  Production of liquisolid systems is similar to that of conventional tablets. 
  Can be used for formulation of liquid oily drugs. 
  Can be used in controlled drug delivery. 
LIMITATIONS 
  Not applicable for formulation of high dose insoluble drugs. 
  If more amount of carrier is added to produce free-flowing powder, the tablet 
weight increases to more than one gram which is difficult to swallow. 
  Acceptable compression properties may not be achieved since during 
compression liquid drug may be squeezed out of the liquisolid tablet resulting in 
tablets of unsatisfactory hardness. 
APPLICATIONS  
  Liquisolid compact technology is a powerful tool to improve bioavailability of 
water insoluble drugs. Several water insoluble drugs on dissolving in different 
non-volatile solvents have been formulated into liquisolid compacts. 
 Literature cites different drugs successfully incorporated into liquisolid compacts. 
 Rapid release rates are obtained in liquisolid formulations. 
 These can be efficiently used for water insoluble solid drugs or liquid lipophilic 
drugs. 
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 Sustained Release of drugs which are water soluble drugs such as propranolol 
hydrochloride has been obtained by the use of this technique. 
 Solubility and dissolution improvement  
 Flowability and compressibility  
 Designing of Controlled Release Tablets 
 Bioavailability Enhancement  
 Application in probiotics. 
 The possibility of using liquisolid technique as a promising alternative to 
conventional coating for the improvement of drug photostability. 
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CHAPTER - II 
LITERATURE REVIEW 
Vinod valjibhai siju et al.,(2017) improved the dissolution rate of the drug, 
cilnidipine (CLD) by using the liquisolid compact technique and wet granulation.cildipine 
drug is poorly soluble in water and it’s highly soluble in higher pH.in this study drug is 
solubilize in tween 80 and sodium hydroxide and meglumine solution. And then drug 
solution binding on pearlitol SD 200. PVCP K30 used as a binder and crospovidone 
used as disintegrant. Sodium hydroxide and meglumine used as a buffering agent for 
basic media preparation.the drug release rates of tablets which prepared by liquisolid 
compact have higher solubility and dissolution then conventional tablets. 
Mamatha and sulthana.,(2017) developed new formulation to enhance the 
solubility of a highly permeable and a poorly soluble oral drug antihyperglycemic agent, 
nateglinide by liquisolid compacts. The liquisolid compact technique is based on 
dissolving the insoluble drug in propylene glycol, polyethylene glycol 400, tween-80 as 
non-volatile solvents in which drug is having high solubility and admixture of drug 
loaded solution with microcrystalline cellulose as carrier, aerosil as coating material, 
crospovidone as disintegrant, and magnesium stearate as lubricant to convert into 
acceptably flowing and compressible powder. The prepared liquisolid compacts were 
evaluated for their flowing properties such as bulk density, tapped density, angle of 
repose, Hausner’s ratio, and Carr’s index. Further tablets were evaluated for hardness, 
thickness, weight variation, friability, disintegration test, and in vitro release study. From 
this higher drug release profiles due to increased wetting property and surface area of 
the drug available for dissolution was obtained in case of liquisolid compacts. Among all 
formulations, liquisolid system prepared by propylene glycol was considered as best 
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formulation which release drug up to 98% in 60 minutes and in comparison to marketed 
formulation, optimized formulation showed better dissolution profile. 
Dias et al.,(2017)  had  prepared liquisolid compacts of high dose water insoluble 
drug, carbamazepine (CBZ) using novel porous carriers such as Neusilin and Fujicalin 
in order to improve its dissolution rate and reduce the tablet weight.  Solubility of CBZ 
was determined in different non volatile solvents to finalise vehicle having maximum 
solubility. The liquid retention potential (Φ) of carriers and coating material was 
determined and 18 different liquisolid compacts of CBZ were formulated. The prepared 
liquisolid compacts were evaluated and compared for thickness, diameter, weight 
variation, uniformity of content, hardness, friability, disintegration and in vitro dissolution. 
Dissolution profile of liquisolid compacts was compared with marketed tablet 
formulation.  The solubility of CBZ in polyethylene glycol 200 was found to be greater 
than the other solvents. Neusilin showed higher Φ value than traditional carriers. 
Formulated liquisolid compacts showed all physical parameters within prescribed limit. 
Formulation containing Neusilin-Neusilin and Neusilin- Aerosil showed no disintegration 
while all other formulations showed disintegration up to 180 seconds. All the 
formulations showed drug release above 80% at the end of 15 minutes except marketed 
formulation. The weight of formulations containing Neusilin and Fujicalin ranged in 
between 0.383-0.947g. Formulation FA3 containing Fujicalin exhibited lower mean 
dissolution time and higher dissolution efficiency than all other formulations including 
marketed tablet. 
Mustafa E et al., (2017) had designed orodispersible tablets of zolmitriptan by 
using liquisolid technique. Orodispersible tablets were prepared by using propylene 
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glycol, avicel PH-102 and aerosil 200 as a non-volatile solvent, carrier material and 
coating material respectively and various types of super disintegrating agents such as 
croscarmellose sodium, sodium starch glycolate, and crospovidone to facilitate faster 
disintegration of the liquisolid compact. 
The overall results showed that among the three super-disintegrants, 
crospovidone was the best super disintegrant showing the shortest disintegration time 
while loading factor of 0.125 was the best in the preparing of zolmitriptan liquidsolid 
orodispersible tablets . 
Patil,et al.,(2016) formulated and evaluated liquisolid compact system of 
carvedilol to give increased dissolution rate of drug by utilizing PEG400 as the non-
volatile liquid vehicle. The liquisolid tablets formulated with PEG400 at different 
concentrations and the suitable analytical method based on UV-visible 
spectrophotometer was developed for carvedilol. The results of differential scanning 
calorimeter and Fourier transform infrared analysis confirmed that the excipients are 
compatible with the drug. The liquisolid tablets formulated with PEG400 at drug 
concentration 20% w/w is the best formulations among the other 10 batches of liquisolid 
tablet prepared, in terms of superior dissolution profile. LSC3 with R value 15 gave the 
maximum drug release. Short term accelerated stability study of optimized formulation 
(LSC3) of carvedilol was carried out at 40°C ± 2°C and at 75% ± 5% RH for 1 month. 
Padmapreetha J et al., (2016) had formulated liquisolid compact to enhance the 
dissolution rate of leflunomide by using kolliphor EL, avicel PH 102, aerosol, and 
sodium starch glycolate as a non-volatile solvent, carrier, coating material and super 
disintegrant respectively. The results showed that during the first 10 min (Q
10%
) the 
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optimized formulation released 73.39% of its content compared to 18.94 % of the 
conventional formulation. In conclusion, leflunomide dissolution rate can be enhancing 
to a greater extent by liquisolid technique 
Mowafaq MG et al., (2015) had prepared liquisolid compact for solubility 
enhancement of tenoxicam using tween 80 as a non-volatile liquid, avicel PH102 as a 
carrier, and aerosil 200 as a coating material. Liquisolid formulations containing various 
drug concentrations in liquid medication ranging from 10% to 35% w/w were prepared. 
Liquisolid formulations showed greater drug release rates than conventional and 
marketed tablets due to increasing surface area of the drug and wetting properties. 
Zafar et al (2015)., had compared Liquid-solid technique and solid dispersion 
formation which are two novel approaches for enhancement of dissolution rate of BCS 
class II drugs. Liquisolid compact converts a liquid drug or drug solution into a free 
flowing powder with enhanced dissolution rate. In case of solid dispersion drug is 
molecularly dispersed in a hydrophilic polymer in solid state. In the present study, 
Liquisolid and solid dispersion techniques were applied to enhance the dissolution of 
the Hydrochlorothiazide. Three formulations of Hydrochlorothiazide were prepared by 
Liquisolid technique using micro crystalline cellulose as carrier material and colloidal 
silicon dioxide as coating material. Water, poly ethylene glycol- 400 and Tween-60 were 
used as solvent system. Solid dispersions of Hydrochlorothiazide were prepared by 
solvent fusion method using PEG-4000 as carrier polymer. Tablets were subjected to 
evaluation of various physical and chemical characteristics. Dissolution profiles of 
tablets prepared by the novel techniques were compared with marketed conventional 
tablets. Model independent techniques including similarity factor, dissimilarity factor and 
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dissolution efficiency were applied for comparison of dissolution profiles. The results 
obtained indicated that liquid solid compact formulations were more effective in 
enhancing the dissolution rate compared with solid dispersion technique. The Liquisolid 
compacts improved the dissolution rate up to 95% while the solid dispersion increased it 
to 88%. 
Ayesha et al (2015)., had prepared Liquisolid compacts using polyethylene 
glycol 400, propylene glycol and Tween-80 as non-volatile solvents. Neusilin as carrier 
material and Aerosil-200 as coating material for enhancement of dissolution rate of 
Olmesartan medoxomil. From the study, it was concluded that the dissolution studies for 
Liquisolid compacts and conventional formulations were performed and it was found 
that Liquisolid compacts with Neusilin and Tween-80 showed significant higher drug 
release than conventional 
Prakash et al (2014)., had investigated Liquisolid powder compacts (LSPCs) 
proved to be the potential solubility improvement strategy for efficient oral delivery of 
BCS class II and IV drugs. The LSPCs were formulated using propylene glycol as non-
volatile solvent. The effect of different formulation variables on LSPCs performance was 
evaluated using 32 factorial design. The selected independent variables were % of 
clonazepam in propylene glycol (X1) and % of sodium starch Glycolate (X2) and 
dependent variables were disintegration time (YDT) and % cumulative drug release at 
15th minute (YQ15). LSPCs of CLZ formulated with propylene glycol at optimum drug 
concentration produced high dissolution profile with acceptable tablet properties. Fourier 
transform infra-red spectroscopy (FTIR) studies revealed that there was no interaction 
between drug and polymers, differential scanning calorimetry (DSC) and X Ray 
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Diffraction (XRD) indicated conversion of crystalline to amorphous form of the CLZ. The 
permeation studies carried out in isolated rat intestine revealed that potential of LSPCs 
for enhanced permeation of CLZ across rat intestinal barrier. The increase in 
permeation of clonazepam from LSPCs formulation across rat intestine suggests the 
potential of LSPC formulation for improved oral delivery of CLZ. In conclusion, the 
present study showed that LSPC technique could be a promising strategy in improving 
dissolution of poorly water soluble CLZ and wettability was improved by making a 
suspension in propylene glycol, the water soluble, nonvolatile solvent. LSPCs could be 
prepared using MCC PH 102 as a carrier, and AEROSIL® 200 as a coating material. 
The FTIR studies revealed that excipients were compatible with the drug. DSC and 
XRD studies showed that there is a decrease in crystallinity of the CLZ in Liquisolid 
compact formulation. A fall in crystallinity means improved dissolution release profile. 
The optimized formulation showed higher dissolution rate when compared with that of 
pure drug. 
Elkordy et al., (2014), had investigate dissolution behavior of norfloxacin as a 
model hydrophobic drug through application of Liquisolid technology. Norfloxacin was 
prepared as Liquisolid formulations using either flowability or compressibility Liquisolid 
tests. The dissolution profiles were evaluated and compared to counterpart conventional 
norfloxacin tablets. Two non-volatile liquid vehicles were used in the preparation of 
norfloxacin Liquisolid formulations; Poly Ethylene Glycol (PEG200) and Synperonic 
PE/L-61. The Liquisolid formulations of norfloxacin were tested according to the 
specification of British Pharmacopoeia (BP) quality control tests. Moreover, the pre-
preparation evaluation tests, such as powder flowability Carr’s index, differential 
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scanning calorimetry (DSC) and Fourier transform infrared (FT-IR), were applied for 
further investigation of the physicochemical properties of the Liquisolid formulations. 
The results indicated that the percentage of norfloxacin release in acetate buffer 
solution (pH = 4.0) is higher than in distilled water. Also, at the first 20 min, the 
percentage of the drug release is higher only in the decreased amount of liquid vehicle 
formulations compared with the conventional tablet. Generally, the conventional tablet 
dissolution profile is either similar or higher than Liquisolid tablets. Moreover, 
Synperonic PE/L-61 Liquisolid tablets showed higher dissolution profiles than PEG200 
Liquisolid tablets, although the solubility of norfloxacin in PEG200 (2.507 mg/ml) is 
much higher than in Synperonic PE/L-61 (0.167 mg/ml). In conclusion, increasing the 
percentage of liquid vehicle in the prepared norfloxacin Liquisolid formulations does not 
necessarily lead to increase in the percentage of the drug release in distilled water 
dissolution medium 
Yousef et al., (2014), had investigated the effect of solvent type on Diltiazem 
hydrochloride release profile from Liquisolid compacts. To examine aforementioned 
idea, the drug solubility was studied in several conventional nonvolatile solvents. 
Liquisolid formulations of diltiazem HCl in the different solvents were prepared and their 
release profiles were also obtained. Effect of aging on the hardness and drug release 
profile was studied as well. X-ray crystallography and differential scanning calorimetry 
(DSC) were used to investigate the formation of any complex between drug and carrier 
or any crystallinity changes during the manufacturing process. The results showed that 
diltiazem HCl had lowest solubility in polysorbate 20. Highest amount was devoted to 
polysorbate 80 and propylene glycol. Type of nonvolatile solvent and its 
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physicochemical properties as well as solubility of the drug in the applied solvent found 
to have important role on release profile of the drug from Liquisolid compacts. Hardness 
and dissolution profile of the drug were not affected by aging. Amorphous form was 
obtained during the process of Liquisolid formulation. It follows that the optimized new 
technique can be used to prepare sustained release formulations of water-soluble 
drugs. 
Srinivas et al., (2014), had improved the solubility and dissolution rate of poorly 
soluble drug Piroxicam by using Liquisolid technique. This technique of delivering drugs 
is suitable mostly for lipophilic drugs and poorly water soluble drugs. However, an 
apparent limitation of this technique is the formulation of a high dose because a large 
amount of liquid vehicle is needed, which finally results in a low-dose liquid solid 
formulation. This approach is suitable for both immediate and sustained release 
formulations. Solubility is increased by using non-volatile solvents such as PEG 400, 
Labrosol, Span20 and Tween 80 in single or combination which are suitable for drug 
and dissolving the drug in those nonvolatile solvents, which is termed as ‘liquid 
medicament’. The liquid medicament is blended with carriers such as microcrystalline 
cellulose and Aerosil to convert the liquid medicament into a non-adhering, dry looking 
powder which has acceptable flow properties and compression behavior. These 
Liquisolid systems are evaluated by micromeritics studies like flow behavior, bulk 
density, tapped density, compressibility index, drug content, in vitro release, Fourier 
transform infra-red spectroscopy and powder X-ray diffraction. He concluded that 
dissolution rate and bioavailability of poorly water soluble drugs like Piroxicam can 
increased by applying Liquisolid technology. He also observed, In-vivo drug release 
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study of Liquisolid compacts using animal model to claim success in the development of 
Liquisolid compacts of Piroxicam. 
Iizhar S. and Bhavani (2014), had studied the effect of carrier: coating ratio, 
concentration of disintegrant and non-volatile solvents on disintegration time and 
dissolution rate in the formulation of Liquisolid compacts of Nateglinide. An apparent 
limitation of this technique is the formulation of a high dose because a large amount of 
liquid vehicle is needed, which finally results in a low-dose liquid solid formulation. NTG 
was dispersed in PEG-400 as a liquid vehicle. Then a binary mixture of carrier–coating 
materials (MCC- Aerosol) was added to the liquid medication under continuous mixing. 
Precompression studies, such as flow properties were also carried out. The formed 
mixture was compressed to get tablets matrices by using the tableting machine. The 
prepared Liquisolid tablets were evaluated by hardness, friability, disintegration test and 
in vitro dissolution studies. The dissolution property of a water-insoluble drug 
Nateglinide (NTG) was investigated. The dissolution profile of the prepared Liquisolid 
tablets was also compared to that of a marketed formulation (MR). The results indicate 
that Liquisolid based tablets (F3) showed greater disintegration and dissolution rate. It 
might be due to the presence of PEG-400 as it showed the enhancement in the 
solubility of NTG. FT-IR results showed compatibility of Nateglinide with excipients 
used. He concluded that as the carrier: coating ration increases with the concentration 
of disintegrant, disintegration and dissolution rate of Liquisolid compacts of Nateglinide 
was increased. 
Poluri et al., (2014), had formulated fast disintegrating tablets by using Liquisolid 
technology. Sodium starch Glycolate, crospovidone are used as superdisintegrant in 
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this invention to reduce disintegration time by which fast absorption can take place 
which ultimately increase dissolution of the drug. As a result of comparison with 
marketed formulation using similarity dis-similarity factor, both formulations shows 
similar in-vitro dissolution profile of Lamotrigine. 
Manish et al., (2014), had developed a novel liquid solid technique which 
enhances the dissolution rate of water insoluble or poorly water soluble drugs of 
Nilvadipine, which belong to class II of BCS. Liquisolid Formulations shows better 
Flowability, Compressibility, improves solubility, dissolution and better absorption. Rapid 
disintegration rates are observed compared to conventional tablets and therefore, they 
show improved release rates and hence greater bioavailability. The use of non-volatile 
solvent in the formulation causes increased wettability of water insoluble drugs and 
ensures molecular dispersion of drug in the formulation. 
Jyothi et al., (2014), had enhanced the dissolution rate of Glyburide which is 
insoluble in water. Different formulations were prepared by using different vehicles and 
carriers and Aerosil is used as the coating material. The empirical method as introduced 
by Spireas and Bolton was applied to calculate the amounts of coating and carrier 
materials required to prepare glyburide Liquisolid tablets. In vitro dissolution profiles of 
the Liquisolid formulations were studied and compared with conventional formulation in 
0.1N HCl. It was found that Liquisolid tablets formulated with PEG 400 and Avicel 
pH102 produced high dissolution profile and they showed significant higher drug 
release rates than conventional tablets due to increase in wetting properties and surface 
of drug available for dissolution. Drug-excipient interaction studies showed that there is 
no interaction between the drug and excipients. In conclusion, development of glyburide 
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Liquisolid tablets is a good approach to enhance the dissolution rate which increases 
bioavailability. 
Ujwala R., Venkateswara R. and Navaneetha (2014), had developed a novel 
liquid-solid technique to enhance the dissolution rate of candesartan which is poorly 
water soluble drug which is a BCS class II drug. The selection of non-toxic hydrophilic 
solvent, carrier, coating excipients and its ratios are independent of the individual 
chemical entities which is indirectly leads to enhancement of bioavailability. Liquisolid 
tablets were prepared by using PEG -400, PG as non-volatile liquid vehicles and Avicel 
PH 102, Aerosil 200 as carrier and coating materials, CCS as super disintegrants 
respectively. Among all formulations F7 was shown best drug release and result shows 
increased dissolution profile i.e., 98.1% with polypropylene glycol. The invitro dissolution 
study confirmed enhanced drug release from liquid solid compacts compared with 
conventional and marketed tablets. 
Hitesh J et al., (2014) had compared liquisolid and inclusion complexation 
techniques for dissolution rate enhancement of valsartan. This study was designed for 
screening of suitable non-volatile liquid solvent for the preparation of liquisolid compact 
such as tween 80, polyethyleneglycol 400 and propylene glycol by using the 
mathematical equation. The study was also aimed for enhancement of dissolution rate 
and comparison of liquisolid technique with inclusion complex of β-cyclodextrin. The 
liquisolid formulation showed highest dissolution rate compared with directly 
compressed tablet, pure drug, and formulation prepared by complexation technique 
Yesubabu B et al., (2014) had formulated fast disintegrating tablets of 
lamotrigine using different super disintegrating agents such as crospovidone, sodium 
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starch glycolate. Various batches of liquisolid tablets were prepared. Formulations 
consisting of sodium starch glycolate were found to be fulfilling all the parameters 
satisfactorily when compared with crospovidone. In-vitro, drug release studies showed 
that within 30 min almost 90% of the drug was released from all the formulations 
confirming enhancement of drug dissolution by liquisolid technique 
Ahmed S. Abdul Jabbar et al., 2013, formulated and evaluated piroxicam 
liquisolid compact different liquisolid compacts were prepared using a mathematical 
model to calculate the required quantities of powder and liquid ingredients to produce 
acceptably flowable and compressible admixture. The liquisolid formulation which 
might be attributed to the formation of hydrogen bonding between the drug and liquid 
vehicle this resulted in drug dissolution enhancement. 
Amal Ali Elkordy et al., 2013, studied spironolactone release from liquisolid 
formulations prepared with capryol 90, solutol HS-15 and kollicoat SR 30D as 
nonvolatile  liquid vehicles were used in the design of spironolactone liquisolid 
formulations, capryol 90, synperonic PE/L61 in combination with solutol HS-15 at a ratio 
of 1:1 and kollicoat SR 30D. Spironolactone liquisolid formulations were tested 
according to British Pharmacopoeia (BP) quality control tests. Liquisolid powder 
formulations formulated from a combination of synperonic PE/L61- solutol HS showed 
highest dissolution. The liquid vehicles used with spironolactone liquisolid formulations 
enhanced drug dissolution rate. 
Jarag Ravindra Jagannath et al., 2013, formulated and evaluated sustained 
release liquisolid tablets of metoprolol succinate. This is directed towards the 
development of liquisolid compact for the production of sustained release tablet of water 
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soluble drug. Liquisolid compacts were prepared by using Tween 80 as the liquid 
vehicle or nonvolatile solvent. Avicel PH 102 as absorbing carrier and Aerosil 200 as 
adsorbing coating material. Tween 80 has plasticizer effect by which it can reduce the 
glasstransmission temperature of polymer and impart flexibility in sustaining the release 
of drug from liquisolid matrices. The results showed that wet granulation  are markable 
impact on the release rate of drug from liquisolid compacts reducing the release rate of 
drug from liquisolid compacts. 
Gandhi K.J. et al., 2013, formulated, characterized and evaluated the liquisolid 
tablet containing pioglitazone HCl. The invitro release pattern of liquisolid tablets and 
directly compressed tablets were studied using USP-2 apparatus. The study concludes 
that the liquisolid technique is a promising alternative and best suitable method for 
enhancing solubility. 
Pandey A. et al., 2013, carried out project on dissolution rate enhancement of 
BCS Class II drug paliperidone by spray drying. The technique adopted is very well 
used industrially for preparing amorphous composition of poorly soluble crystalline 
drugs. In case of spray drying PAL with different classes of hydrophilic carriers (different 
grades of polyvinyl pyrolidones [PVPs, plasdones] and cellulosic polymers) were taken. 
Significant enhancement in dissolution rate was observed with the prepared spray dried 
compositions and out of three grades of plasdone; plasdone K12 demonstrated the 
maximum enhancement in rate of release of PAL. Spray drying of PAL with plasdones, 
especially plasdone K12 reduced drug crystallinity, increased rate and extent of 
dissolution. 
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Pande V. V. et al., 2013, enhanced dissolution rate of rosuvastatin calcium by 
liquisolid compact technique. In this technique, liquid medications of water insoluble 
drugs in non-volatile liquid vehicles can be converted into acceptably flowing and 
compressible powders. As liquisolid compacts demonstrated significantly higher drug 
release rate, they lead to a conclusion that it could be a promising strategy by improving 
the dissolution of poor water soluble drugs and immediate release solid dosage forms. 
Amal Ali Elkordy et al., 2012, performed liquisolid technique to enhance and 
sustain griseofulvin dissolution effect by using non-volatile liquid vehicles. They studied 
the effects of different liquid vehicles on release characteristics. Fast dissolution tablets 
were prepared using three different non-ionic surfactants namely cremophor EL, 
synperonic PE/L61 and capryol 90; on the contrary kollicoat SR 30P were used for 
production of sustained release formulations. Avicel PH102 and cab-O-sil M5 were used 
as a carrier and coating materials respectively. Cremophor EL showed the best 
dissolution enhancement with % PE of about 90% compared to only 23% of 
conventional tablets. 
Burra shashidher et al., 2012, formulated and evaluated carvedilol liquisolid 
tablets. A novel powder solution technology involves absorption and adsorption 
efficiency, which makes use of liquid medications, admixed with suitable carriers, 
coating materials and formulated into a free flowing, dry looking, non-adherent and 
compressible powder forms. The crystalline state of drug is changed to amorphous 
state due to liquisolid formation and is confirmed by both DSC and X-ray diffraction 
results. The amorphous form exhibited increased wetting properties because of 
subsequent increased surface area of the particle size. 
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Shah C.V.et al., 2012, designed, developed and optimized valsartan liquisolid 
tablets using Box – Behnken design. This study was designed to optimize and evaluate 
the effects of different formulation variables. Amount of liquid (X1),ratio of carrier to 
coating material (X2) and amount of magnesium oxide (X3) on angle of repose (Y1), 
hardness (Y2) and invitro release (Y3) of formulation using three level Box –Behnken 
stastical design. The non–linear quadratic model generated by the design in the form of 
Y=A0 + A1X1 + A2X2 + A3X3 + A4X1X2 + A5X2X3 + A6X1X3 + A7X12 + A8X22 + 
A9X32 + E, where y is the measured response surface plots were depicted based on 
the equation given by the model. 
Dnyanesh walunj et al., 2012, formulated and evaluated tamoxifen citrate 
liquisolid compacts were prepared using a mathematical model to calculate the 
requiredquantities of powder and liquid ingredients to produce acceptably flowable 
andcompressible admixture. Avicel PH 102, Aerosil 200, croscarmellose sodium 
andpropylene glycol were employed as carrier, coating material, disintegrant and 
nonvolatile solvent respectively for preparing liquisolid compact. This study was 
concluded that liquisolid technique is a promising alternative for improvement of 
dissolution property of water insoluble drugs. 
Sateesh kumar Vemula et al., 2012, enhanced dissolution rate of nimesulide 
byliquisolid technique. Liquisolid tablets were prepared by using polyethylene glycol 400 
as a non-volatile liquid vehicle, microcrystalline cellulose, hydroxyl propyl methyl 
cellulose E-15, starch were used as carrier materials and silica gel as coating material 
in different ratios. Invitro dissolution profiles of liquisolid formulations were studied and 
compared with conventional formulation in pH7.4 phosphate buffer and it was found that 
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liquisolid tablets formulated with microcrystalline cellulose showed significant higher 
drug release rates than conventional tablets due to increase in wetting properties. 
Sidharth patil et al., 2012, formulated and evaluated liquisolid tablets of non 
steroidal anti inflammatory drug ibuprofen were prepared by using microcrystalline 
cellulose (Avicel PH 101) as a carrier material, silica gel as coating material, poly 
ethylene glycol 400 as non – volatile water miscible liquid vehicle and 5%sodium starch 
glycolate used as super disintegrating agent. The results showed that liquisolid 
formulations of ibuprofen exhibited higher percentage of drug release than marketed 
formulation. 
Kamalakannan V. et al., 2012, formulated and evaluated tinidazole liquisolid 
tablets. A liquisolid system is formed by converting a liquisolid formulation into a dry, 
free-flowing and compressible powder mixture with selected carrier material and coating 
material. Liquisolid tablet formulation by using 20:1 ratio of powder excipients ratio 
(480mg of Avicel and 24mg of Cab-O-sil) and 100% w/w tinidazole in PG 600 solvent 
were satisfying the requirements. 
Sirisha V.N.L. et al., 2012, prepared and evaluated (in vitro) liquisolid compacts 
of glibenclamide. Liquisolid tablets were prepared by using PEG 400 as non- volatile 
liquid vehicles and Avicel PH 101, Aerosil as carrier and coating materials respectively. 
The properties of glibenclamide particles were changed by dispersing the drug particles 
in a non–volatile liquid vehicle, which in turn increases the wetting properties and 
surface area of drug particles, and hence improve the dissolution profiles and oral 
bioavailability of the drug. 
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Lakshmi P.K. et al., 2011, prepared and comparatively evaluated liquisolid 
compacts and solid dispersions of valsartan. Liquisolid technology and solid dispersion 
by kneading method used to improve the solubility of the drug by using non-
volatilesolvents. Various non-volatile solvents were used such as PG, PEG and 
glycerin. The carrier and coating material play an important role in improving the 
solubility of the drug. Solid dispersion by kneading method is another attempt to 
improve solubility. Various carrier materials were used such as PVP K30, PEG 6000 
and mannitol. These carriers were used in various ratios to improve its solubility. The 
results concluded that the liquisolid compacts enhanced the solubility of valsartan in 
comparison to traditional solid dispersion method. 
Vijayakumar Nagabandi et al., 2011, formulated, developed and evaluated 
liquisolid systems to improve the dissolution rate of ketoprofen using different carrier 
materials such as microcrystalline cellulose (Avicel PH101), starch, dicalcium 
phosphate, lactose and silica gel as coating material. Polyethylene glycol 400 was used 
as non-volatile water miscible liquid vehicle. The ratio of carrier to coating material was 
kept constant in all formulations of ketoprofen which exhibited higher percentage of drug 
release than marketed formulation. 
Vijayakumar Nagabandi et al., 2011, formulated, developed and evaluated 
liquisolid systems to improve the dissolution rate of naproxen with two different liquid 
vehicles, namely polyethylene glycol 400 and propylene glycol. Two different carrier 
materials were used namely microcrystalline cellulose (Avicel PH101) and dicalcium 
phosphate. Silica gel as coating material and sodium starch glycolate as disintegrating 
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agent in all formulations. The results showed that liquisolid formulations of ketoprofen 
exhibited higher percentage of drug release than marketed formulation. 
Ali Nokhodchi et al., 2010, studied the effect of co solvent and HPMC on 
theophylline release. Liquisolid tablets were prepared by mixing liquid medication with 
silica. Eudragit RL or RS followed by the compaction of the mixture. For comparison 
purposes physical mixtures of all ingredients were prepared. The effect of liquid 
medication and HPMC concentration on drug release was investigated. The sustained 
release action of HPMC was enhanced in liquisolid compacts in comparison to simple 
sustained release matrix tablets. 
Amal A. Elkordy et al., 2010, developed liquisolid systems to improve the 
dissolution rate of furosemide were prepared using microcrystalline cellulose 
(AvicelPH101)as carrier and fumed silica (Cab-O-sil M-5) as coating material. 
Polyethylenepolyoxypropylene- polyoxyethylene block copolymer (Synperonic PE/L81) 
1, 2, 3 propranolol, homopolymer, (a2) 9-octadecenoate (caprol PGE-860) and 
polyethylene glycol 400 (PEG 400) were used as non-volatile water miscible liquid 
vehicles. The results showed that all formulations exhibited higher percentage of drug 
dissolved in water (pH6.4-6.6) compared to that of acidic medium (pH1.2). Liquisolid 
compacts containing synperonic PE/L81 showed higher release rate at different pH 
values. Formulations with PEG 400 displayed lower drug release rate compared to 
conventional tablet. 
Amrit B. Karmarkar et el., 2010, evaluated (in vitro) dissolution profile 
comparisonmethods of sustained release tramadol hydrochloride with marketed 
sustained release tablets. Liquisolid sustained release formulations were prepared by 
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using HPMC K4M as a sustained release agent. Liquisolid compacts were evaluated 
.The dissolution profile followed the Peppas model as “best fit”. Two-way ANOVA 
results revealed a significant difference in dissolution profiles. This systematic approach 
to producing a formulation was found to help with analyzing the sustained release of 
tramadol hydrochloride. 
Dinesh M. Pardhi et al., 2010, developed liquisolid technique for enhancement 
of dissolution properties of carvedilol. The invitro release pattern of liquisolid compacts 
and directly compressed tablets were studied using USP-2 apparatus. From this study it 
concludes that the liquisolid technique is a promising alternative for improvement of 
dissolution property of water insoluble drugs. 
Khalid M. El-Say et al., 2010, formulated and evaluated rofecoxib liquisolid 
tablets.The effect of powder substrate composition on the flow ability and 
compressibility of liquisolid compact were evaluated specifically several liquisolid 
formulation containing 25mg rofecoxib using different carrier to coating ratios in their 
powder substrates and fixed liquid medication were prepared. From the previous 
results, it was concluded that addition of 10 % Cab-O-Sil and 5% magnesium oxide 
improved both the flow ability and compressibility of tested rofecoxib powders. These 
two substances change the flow ability from bad flow to satisfactory flow. The prepared 
liquisolid tablets showed higher dissolution profile than the three studied commercial 
tablet. 
Shashibher Burra et al., 2010, enhanced the solubility and dissolution rate of 
furosemide through liquisolid technique. The drug dissolution was tested using different 
dissolution media such as 1.2pH, 5.4pH, 6.8pH, 7.4pH. The results showed that liquid 
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solid tablets have higher drug dissolution rates than the conventional and directly 
compressible tablet 
Sanjeev raghavendra Gubbi et al., 2010, formulated and characterized 
atorvastatin calcium liquisolid compact were prepared using a mathematical model for 
calculating required quantities of powder and liquid ingredients to produce an 
acceptably flowable and compress able admixture. Avicel PH102, Aerosil 200 and 
Explotab were employed as carrier, coating material and disintegrant respectively. This 
study shows that the liquisolid technique is a promising alternative for improvement of 
the dissolution rate and oral bioavailability of water insoluble drugs confirmed by 
estimating the pharmacokinetic parameters in vivo in rabbits. 
Amrit B. Karmarkar et al., 2009, enhanced dissolution rate of fenofibrate using 
liquisolid tablet technique. Liquid medications such as solutions or suspensions of water 
insoluble drugs in suitable non-volatile liquid vehicles can be easily converted into 
powders with acceptable flow properties and compression behavior by using powder 
excipients. Enhanced drug release profiles due to increased wetting properties and 
surface of drug available for dissolution was obtained in case of liquisolid tablets. 
Amal A. Elkordy et al., 2009, formulated and evaluated the effects of liquisolid 
formulations on dissolution of naproxen with three different liquid vehicles namely 
cremophor EL, synperonic PE/L61 and polyethylene glycol 400 at two drug 
concentrations 20% w/w and 40% w/w. Avicel PH102 was used as a carrier material, 
Cab-O-sil M5 as a coating material, maize starch as a disintegrant. Liquisolid tablets 
formulated with cremophor EL at drug concentration of 20% w/w produced high 
dissolution profile with acceptable tablet properties. 
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Sanjeev Gubbi et al., 2009, performed liquisolid technique for enhancement of 
dissolution properties of bromhexine hydrochloride. Different LS compacts were 
prepared using a mathematical model to calculate the required quantities of powder and 
liquid ingredients to produce acceptably flowable and compressible mixture. The 
prepared LS compacts were evaluated. From this study it was concluded that the LS 
technique is a promising alternative improvement of dissolution property for water 
insoluble drugs. 
Yadav V.B. et al., 2009, improved solubility and dissolution of indomethacin by 
liquisolid compaction and granulation technique. In the liquisolid system IM was 
dispersed on polyethylene glycol 400(PEG 400) as a non-volatile liquid vehicle. 
Microcrystalline cellulose (Avicel PH102) and dibasic calcium phosphate (DCP) were 
used as a carrier; hydroxypropyl methyl cellulose (HPMC) as coating material and 
sodium starch glycolate (SSG), croscarmellose sodium (CCS) were used as 
disintegrants. It was observed that the drug release rate, water solubility and wettability 
of liquisolid granules containing super disintegrants were on higher side compared to 
liquisolid granules without super disintegrants. 
Ali Nokhodchi et al., 2008, carried out liquisolid technique as a new approach to 
sustain propranolol hydrochloride release from tablet matrices. The drug was dispersed 
in polysorbate 80 as liquid vehicle. Then the binary mixture of eudragit RL or RS 
(carrier) and silica (coating material) was added to the liquid medication under 
continuous mixing in a mortar. The final mixture was compressed using a manual 
tableting machine. The release rate of propranolol HCl from liquisolid compacts was 
compared with that of conventional tablets. The drug prepared by liquisolid technique 
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showed greater retardation properties in comparison with conventional tablets. This 
investigation provided evidence that polysorbate 80 (Tween 80) has important role 
insustaining the release of drug from liquisolid matrices. 
Ali Nokhodchi et al., 2007, studied liquisolid technique as a tool for 
enhancement of poor water soluble drugs and evaluated their physiochemical 
properties. Different formulations of liquisolid tablets, using different co-solvents, (non-
volatile solvents) were prepared and the effect of aging on the dissolution behavior of 
indomethacin liquisolid compacts was investigated. Dissolution test was carried out at 
two different pH, 1.2 and 7.2 to simulate the stomach or intestine fluid respectively. 
Liquisolid compacts containing propylene glycol as vehicle produced higher dissolution 
rates in comparison with liquisolid compacts containing PEG 400 or Tween 80 of the 
same concentration. 
Ali Nokhodchi et al., 2007, enhanced the dissolution rate of high dose water 
insoluble drug (carbamazepine) using liquisolid technique. Different liquisolid 
formulations of drug were accomplished by dissolving the drug in the non–toxic 
hydrophilic liquids and adsorbing dissolution on to the surface of silica. In order to 
reduce the amounts of carrier and Aerosil in liquisolid formulations some additives 
namely polyvinyl pyrolidone (PVP), hydroxypropyl methyl cellulose (HPMC) and 
polyethylene glycol (PEG 35000) were added to liquid medication to increase loading 
factor. The effects of various ratios of carrier to coating material, PVP 
concentration,effect of aging and type of carrier on dissolution rate of liquisolid 
compacts were studied. The results showed that drug loading factors was increased 
significantly in the presence of additives. It was shown that microcrystalline cellulose 
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had more liquid retention potential in comparison with lactose and the formulations 
containing microcrystalline cellulose as carrier, showed higher dissolution rate. by 
decreasing the ratio of microcrystalline cellulose to silica from 20 to 10, an improvement 
in dissolution rate was observed. 
Dina Louis et al., 2007, improved the dissolution properties of carbamazepine 
through application of liquisolid tablet technique. Avicel PH 102 and Aerosil 200 were 
used as carrier and coating material respectively and Explotab was used as disintegrant 
to prepare four tablet formulae, out of which formula 1 was successfully compressed 
into tablets. The prepared tablets showed good wettability, rapid disintegration and 
acceptable dissolution rate comparable to the generic product. 
Nokhodchi A. et al., 2005, enhanced the dissolution rate of piroxicam using 
liquisolid compacts. The dissolution behavior of drug from liquisolid compacts was 
investigated in simulated gastric fluid (SGF pH1.2) and simulated intestinal fluid (SIF 
pH7.2). The results showed that liquisolid compacts demonstrated significantly higher 
drug release rates than those of conventionally made. This was due to an increase in 
wetting properties and surface of drug available for dissolution. 
Khaled A. Khaled et al., 2001, evaluated (in vivo) hydrochlorothiazide liquisolid 
tablets in beagle dogs. The drug was administered orally as a single 25mg dose of 
commercial and liquisolid tablets on two occasions in a randomized two-way cross over 
design. The absolute bioavailability of the drug from the liquisolid tablets was 15% 
higher than that from the commercial one. The parametric 90% confidence intervals for 
the different parameters were higher than the commonly expected intervals for 
bioequivalency, indicating greater bioavailability of the liquisolid tablets. 
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Spiro Spireas et al., 1998, enhanced prednisolone dissolution properties using 
liquisolid compacts. According to the new formulation method of liquisolid compacts, 
liquid medications such as solutions or suspensions of water insoluble drugs in suitable 
non – volatile liquid vehicles can be converted into acceptably flowing and compressible 
powders by blending with selected powder excipients. Liquisolid compacts 
demonstrated significantly higher drug release rates, in different dissolution media and 
volumes, compared to tablets prepared by the direct compression method. 
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CHAPTER-III 
AIM OF THE WORK 
The poor dissolution rate of water insoluble drug is a major impediment to the 
development of pharmaceutical dosage forms. The oral absorption of drug is most often 
controlled by dissolution in the gastrointestinal tract. Different methods are employed to 
improve the dissolution characteristics of poorly water soluble drugs, like solubilization, 
pH adjustment, co-solvents, microemulsion, particle size reduction, use of surfactant as 
a solubilizing agent, prodrug approach etc. Amongst these the most promising method 
for promoting dissolution is the use of the liquisolid system. 
Liquisolid system refers to formulation by con version of oily liquid drug and 
solutions or suspensions of water insoluble solid drugs in non-volatile solvents into dry, 
non-adherent, free flowing and compressible powder mixtures by blending the 
suspension or solution with selected carrier and coating materials. 
Pioglitazone is an orally-active thiazolidinedione with antidiabetic properties and 
potential antineoplastic activity. Pioglitazone activates peroxisome proliferator- activated 
receptor gamma (PPAR-gamma), a ligand- activated transcription factor, thereby 
inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also 
modulates the transcription of insulin- responsive genes, inhibits macrophage and 
monocyte activation and stimulates adipocyte differentiation. 
Pioglitazone is a class II drug of BCS classification; hence it has a low solubility 
and low permeability. Due to the low solubility it has a low oral bioavailability 
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To overcome the drawbacks, various techniques are employed to enhance the 
dissolution of water insoluble drug. Among these the “liquisolid” is a newly developed 
technique. As the drug is in the form of liquid medication, it is in either solubilized or 
molecularly dispersed state. Due to increased wetting and surface area for dissolution, 
liquisolid tablets of water insoluble drugs may show improved dissolution properties and 
in turn increases bioavailability. 
 
The aim of present study is to formulate liquisolid tablets of Pioglitazone  using 
different non-volatile liquid (Propylene glycol, Polyethylene glycol-400 and Tween 80), 
Avicel PH102 as a carrier and Aerosil 200 as a coating material. The best formulation 
selection is on the basis of release pattern and is to be compared with directly 
compressed tablet and pure drug. 
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CHAPTER - IV 
PLAN OF WORK 
 
1.PREPARATION OF STANDARD CALIBRATION CURVE 
a)Determination of λ max 
b)Preparation of calibration curve 
2.SOLUBILITY STUDIES 
3.PREFORMULATION (COMPATIBILITY) STUDIES 
a) Infrared spectroscopic studies 
4.FLOWABLE LIQUID-RETENTION POTENTIAL (Ф-VALUE) OF 
EXCIPIENTS 
a) Determination of the angle of slide 
b) Determination of flowable liquid-retention potential (ф-value) 
5.PROCEDURE FOR PREPARATION OF LIQUISOLID POWDER 
6.PREPARATION OF DIRECTLY COMPRESSED TABLETS 
7.PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
a) Angle of repose 
b) Bulk Density 
c) Tapped Density 
d) Carr’s Index 
e) Hausner’s Ratio 
f) Drug content for Powder Blend 
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8.POSTCOMPRESSIONAL EVALUATION OF LIQUISOLID TABLETS 
a) General appearance 
b) Thickness 
c) Hardness 
d) Weight variation 
e) Friability test 
f) Estimation of drug content 
g) Disintegration test 
9. IN VITRO RELEASE STUDIES 
10. POWDER X-RAY DIFFRACTION STUDIES 
11. ASSESSMENT AND COMPARISON OF DRUG DISSOLUTION RATES 
12. SELECTION AND EVALUATION OF BEST FORMULATION 
a) Comparison of dissolution studies of best formulation with pure drug 
and directly compressed tablets 
b) Infrared spectroscopic studies for best formulation 
c) Differential scanning colorimetric (DSC) studies for best formulation 
d) Drug release kinetics studies 
e) Stability studies 
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MATERIALS AND EQUIPMENTS 
             MATERIALS         DISTRIBUTORS 
Pioglitazone.HCL Madras pharma,Chennai. 
Propylene glycol Pharmafabrikon ,Madurai. 
Polyethylene glycol 400 Pharmafabrikon ,Madurai. 
Tween 80 Universal scientific 
appliances,Madurai. 
Microcrystalline cellulose Madras Pharma,Chennai. 
Aerosil 200 (silica) Micro labs Ltd.Bangalore. 
Crospovidone Ordain health care,Chegalpet 
Magnisum stearate  Madras Pharma,Chennai. 
Talc  Ordain health care.Chennai. 
Methanol  Universal scientific appliances, 
Madurai. 
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             EQUIPMENTS               SUPPLIERS 
Electronic Weighing Balance A & D Company,Japan. 
Multi punch tablet compression machine  Fluid Pack, Ahmedabad  
UV Visible spectrophotometer Shimazdu UV-1700,Japan 
Digital tablet dissolution test apparatus Lab India Disso Apparatus 2000, India. 
Friability test apparatus  Indian Equipment corporation,Mumbai. 
Tablet hardness tester Scientific Equipment Corporation,Mumbai 
Digital Vernier caliper  Linker ,Mumbai. 
Disintegration test apparatus Rolex ,India. 
Fourier transform infrared spectroscopy Shimadzu , Japan. 
Differential scanning colorimeter DSC Q200 V24.4 Instrument,USA. 
Power X-ray diffractometer  XD,Shimadzu,Japan. 
Scanning electron microscopy Hitachi X650,Tokyo,Japan. 
Magnetic stirrer   M.C.Dalal,Chennai. 
Mechanical shaker  Secor ,India 
Stability  Chamber  In labs Equipments (P) Ltd.Madras. 
Hot air oven Industrial Headans, Chennai. 
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CHAPTER-VI 
DRUG  PROFILE 
DRUG NAME   : PIOGLITAZONE.HCL 
STRUCTURAL FORMULA: 
 
CHEMICAL FORMULA: 
  C19H20N2O3S.HCL 
CHEMICAL NAME:   
 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl) 1,3-thiazolidine-2,4-dione]  
MOLECULAR WEIGHT   : 356.44gm/mol 
DESCRIPTION  
 Physical state    : Solid   
 Colour    : White to off white 
 Solubility    :  Soluble in Methanol , N,N-dimethylacetamide,  
                                    Acetic acid ,Slightly solube in  Ethanol, 1-propanol. 
      Practically insoluble in water. 
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Molecular weight   :    356.44 g/mol 
pKa     :   5.6 
LogP  value    : 2.3 
Refractivity    :         97.71 m3.mol-1 
Melting Point   : 183-184OC 
Polarizability   : 37.91  
MECHANISUM OF ACTION 
Pioglitazone acts as a selective agonist at Peroxisome Proliferator Activated 
Receptor Gamma (PPARγ) in target tissues for insulin action such as adipose tissue, 
skeletal muscle, and liver. Activation of PPAR-gamma receptors increases the 
transcription of insulin-responsive genes involved in the control of glucose production, 
transport, and utilization. In this way, pioglitazone both enhances tissue sensitivity to 
insulin and reduces the production of glucose via the liver (hepatic gluconeogenesis). 
Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an 
increase in insulin secretion by pancreatic β cells. 
Pioglitazone acts principally by increasing insulin sensitivity in target tissues, as 
well as decreasing hepatic gluconeogenesis. Pioglitazone is a peroxisome proliferator-
activated receptor (PPAR) agonist that increases transcription of insulin-responsive 
genes and increases insulin sensitivity 
PHARMACOKINETICS 
Absorption 
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 oral administration of Pioglitazone, peak concentrations of pioglitazone were 
observed within 2 hours. Food slightly delays the time to peak serum concentration (T 
max) to 3 to 4 hours, but does not alter the extent of absorption (AUC) 
Volume of Distribution  
 Mean volume of distribution at steady-state of Pioglitazone is approximately 
0.63 ± 0.41 L/Kg 
Protein Binding  
 The plasma protein binding of recemic pioglitazone is >99%. 
Metabolism 
 Pioglitazone is extensively metabolized by hydroxylation and oxidation; the 
metabolites also partly convert to glucuronide or sulfate conjugates. Metabolites M-III 
and M-IV are the major circulating active metabolites in humans. The cytochrome P450 
isoforms involved are CYP2C8 and, to a lesser degree, CYP3A4 with additional 
contributions from a variety of other isoforms including the mainly extrahepatic CYP1A1  
Route of elimination 
 oral administration, approximately 15% to 30% of the pioglitazone dose is 
recovered in the urine. Renal elimination of pioglitazone is negligible, and the drug is 
excreted primarily as metabolites and their conjugates.  
Half Life  
 The terminal elimination half life of Pioglitazone is approximately 3-7 hours. 
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INDICATIONS AND USAGE  
 Adjunct to diet and exercise in type 2 diabetes, as monotherapy or in 
combination with metformin, insulin, or a sulfonylurea. Limitations of use: not for treating 
type 1 diabetes or diabetic ketoacidosis. 
Adult: 
≥18yrs: Without CHF: initially 15mg or 30mg once daily; max 45mg once daily. With 
CHF (NYHA Class I or II): initially 15mg once daily. Concomitant insulin or sulfonylurea: 
reduce dose of these if needed. Concomitant strong CYP2C8 inhibitors: max 15mg 
daily. 
DOSAGE AND ADMINISTRATION  
 Initially, 15 or 30 mg once daily. If response is inadequate, increase dosage in 
increments, up to a maximum dosage of 45 mg daily.If response is inadequate with 
monotherapy, consider combination therapy 
DOSAGE FORMS 
 Tablet,15mg 
 Tablet, 30mg 
 Tablet, 45mg 
CONTRAINDICATIONS 
  hypersensitivity to the active substance or to any of the excipients, 
  cardiac failure or history of cardiac failure (NYHA stages I to IV), 
  hepatic impairment, 
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  diabetic ketoacidosis 
  current bladder cancer or a history of bladder cancer 
  uninvestigated macroscopic haematuria 
 Heart failure 
ADVERSE REACTIONS 
 Muscle pain 
 Weight gain 
 Sore throat 
 Tooth problems 
 Dark urine 
 Plasma volume expension 
 Yellowing of eye / skin 
 Myalgia  
 Headache  
 Mild anaemia 
 Swelling of the face  
OVERDOSAGE 
 Trouble breathing  
DRUG INTERACTION 
Beta-blocker medications (such as metoprolol,propranolol, glaucoma eye drops 
such as timolol) may prevent the fast/pounding heartbeat you would usually feel when 
your blood sugar falls too low (hypoglycemia). 
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  Other symptoms of low blood sugar, such as dizziness, hunger, or sweating, are 
unaffected by these drugs. 
BRAND NAMES 
 Actos (Takeda Pharmaceuticals,U.S) 
 Betapride ( Avunash Pharmaceutical.,India) 
 Diavista  ( Dr.Reddy’s Pharmaceutical Ltd.India) 
 Glizone   ( Zydus Pharmaceuticals Ltd. India) 
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CHAPTER-VII 
EXCIPIENT PROFILE 
PROPLENE GLYCOL 
Synonyms : 
 1,2-Dihydroxypropane 
 2-hydroxypropanol 
 Methyl ethylene glycol 
 Methyl glycol 
 Propane-1,2-diol 
Chemical name: 
 1,2-propanediol 
Empirical  formula: 
 C3H8O2 
Molecular weight: 
 76.09 
Structural formula: 
 
 
CHAPTER -VII                                                                         EXCIPIENT PROFILE 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI-20  57 
 
Functional category: 
 Antimicrobial preservative 
 Plasticizer 
 Water –miscible cosolvent 
 Stabilizer for vitamins 
 Disinfectant  
 Humectants 
HLB value: 
 11.6 
Viscosity at 25 0C 
 58.1mPa s 
Application in pharmaceutical formulation: 
 Propylene glycol has become widely used as a solvent , extractant and 
preservative in a variety of parenteral and nonparenteral pharmaceutical 
formulations. 
 Propylene glycol is commonly used as a plasticizer in aqueous film-coating 
formulations. 
 Propylene glycol is also used in cosmetics and in the food industry as a 
carrier for emulsifiers and as a vehicles for flavors in preference to ethanol, 
since its lack of volatility provides a more uniform flavor. 
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Description: 
 Propylene glycol is a clear, colorless, viscous, practically odourless liquid 
with a sweet acrid taste resembling that of glycerin. 
Melting Point: 
 -590C 
Solubility: 
 Soluble in acetone, chloroform, ethanol, glycerin and water. 
 
Stability and storage condition: 
 Propylene glycol is chemically stable when ethanol  (95%), glycerin, or 
water 
 Propylene glycol is hygroscopic and should be stored in a well-closed 
container, protected from light ,in a cool ,dry place. 
Incompatibilities: 
 Propylene glycol is incompatible with oxidizing reagents such as potassium 
permanganate. 
Handling Precaution: 
 Propylene glycol should be handled in a well-ventilated environment, eye 
protection is recommended. 
(Hand book of pharmaceutical Excipient by Raymond C Rowe.,5th Edition) 
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POLYETHYLENE GLYCOL 400 
Synonyms: 
 Carbowax Sentry 
 Lutrol E 
 Pluriol E 
 Lipoxol 
Chemical name: 
 Polyethylene glycol 400 
Empirical  formula: 
 H(OCH2CH2)nOH 
Molecular weight: 
 400 (380-400) g/mole 
Structural formula: 
 
Functional category: 
 Ointment base 
 Plasticizer 
 Suppository base 
 Tablet and Capsule lubricant 
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HLB value: 
 11.6 
Viscosity at 25 0C 
 105-130 mPas 
Application in pharmaceutical formulation:  
 Polyethylene glycol is widely used in parenteral , topical, ophthalmic and 
oral preparations. 
Description:  
 Clear liquid, odourless 
Melting Point: 
 40C (39.2OF) 
Solubility: 
 Soluble in cold water, hot water, Slightly soluble in aliphatic hydrocarbons. 
Readily soluble in aromatic hydrocarbons. 
Stability:   
 Stable under ordinary condition hygroscopic. 
Storage: 
 Tightly closed container. Keep container in a cool, well-ventilated area. 
Precautions:  
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 Keep away from heat, source of ignition and incompatibles such as 
oxidizing agents, acids, alkalis. 
 Wear suitable protective clothing. 
(www.chemicalland.com and Hand book of Pharmaceutical Excipients by 
Raymond C Rowe.,5th Edition) 
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TWEEN 80 
Synonyms: 
 Armotan PMO 20 
 Capmul POE-0 
 Cremophor Ps 80 
 Montanox 80 
Chemical name:  
 Polyoxyethylene 20 sorbitan monoleate 
Empirical formula: 
 C64  H124 O26 
Molecular weight: 
 1310 
Structural formula: 
 
HLB value: 
 15 
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Functional category: 
 Emulsifying agent 
 Non-ionic surfactant 
 Solubilizing  agent 
 Wetting agent 
 Dispersing / suspending agent 
Viscosity at 250C: 
 425 mPas 
Application in pharmaceutical formulation: 
 They may be used as solubilizing agents for a variety of substances 
including essential oils and oil-soluble vitamins and as wetting agents in the 
formulation  of oral and parenteral suspentions. 
 
 They have been found to be useful in improving the oral bioavailability of  
drug molecules. 
 
 Polysorbates are also widely used in cosmetics and food  products.  
Description: 
 Yellow oily liquid 
Melting point: 
 -20.5560C(-5) 
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Solubility: 
 Soluble in methanol. Easily soluble in cold water .hot water .soluble in 
toluene ,alcohol .cottonseed oil. Ethyl acetate  
 
 Insoluble in mineral oil.  
Stability and storage condition: 
 Polysorbates are stable to electrolytes and weak acids and bases. 
 
 Polysorbate should  be stored in a well-closed container. Protected from 
light  it should be stored in a cool. dry place. 
Incompatibilities: 
 The antimicrobial activity of paraben preservatives is reduced in the 
presence of polysorbates. 
Handling Precaution:  
 observe normal precautions appropriate to the circumstances and quality of 
material handled eye protection and gloves are recommended. 
(Hand book of pharmaceutical Excipient by Raymond C Rowe..5th  Edition) 
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MICROCRYSTALLINE CELLULOSE 
Synonyms : 
 Avicel PH 
 Crystalline cellulose  
 Cellet 
 Emcocel  
 Hellulosum microcristalinum 
Chemical name: 
 Cellulose  
Empirical  formula: 
 (C6H10O5)n 
Molecular weight: 
 36000 gm/mol 
Functional category: 
 Adsorbent  
 Suspending agent  
 Tablet and capsule diluents 
 Tablet disintegrant 
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Structural formula: 
 
Application in pharmaceutical formulation:  
 Microcrystalline cellulose is widely used in pharmaceuticals. Primarily used  
as binder / diluents in oral tablets and capsule formulation. 
 Micerocrystalline cellulose is also used in cosmetics and food products. 
Description : 
 Microcrystalline cellulose is a white, odourless, tasteless, crystalline powder 
composed of porous particles. 
Melting Point: 
 260-2700C 
Solubility : 
 Slightly soluble in 5% w/v NaOH  solution ,practically insoluble in water and 
most organic solvents.  
Solubility and storage condition:  
 Microcrystalline cellulose is stable though hygroscopic material. 
 It should be stored in a well-closed container in a cool, dry place. 
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Incompatibilities: 
 Microcrystalline cellulose is incompatible with strong oxidizing agent. 
Handling Precautions: 
 Microcrystalline cellulose may be irritant to the eyes, Gloves, eye protection 
and dust mask are recommended.  
( Hand book of pharmaceutical Excipient by Raymond C Rowe.,5th Edition) 
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SILICA 
Synonyms: 
 Aerosil 
 Cab-O-sil 
 Colloidal silica 
 Fumed silica 
 Fumed silicon dioxide 
 Silicone dioxide colloidal  
Chemical name: 
 Silicon dioxide 
Empirical  formula: 
 SiO2 
Molecular weight: 
 60.08 
Functional category: 
  Adsorbent 
 Anticaking agent 
 Glidant and Tablet disintegrant 
 Emulsion stabilizer 
 Viscosity increasing agent 
Application in pharmaceutical formulation: 
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  It is improves the flow properties of the dry powders. 
  It is used as an adsorbent dispersing agent for liquids in powders. 
  Eliminate hard settling and minimize the clogging of spray nozzle 
Description: 
 Colloidal silicone dioxide is a light, loose, bluish-white coloured, tasteless, 
odourless and amorphous powder. 
Melting Point: 
 1600oC 
Solubility: 
 Soluble in hot solution of alkali hydroxide. Practically insoluble in water, 
organic solvents and acids. 
Storage condition: 
 It should be stored in a well closed container. 
Incompatibilities: 
 It is incompatibility with diethylstilbesterol preparations. 
Handling Precautions: 
 A dust mask should be used, when handling small quantity. For large 
           quantities, a dust respirator is recommended. 
(www.chemicallab.com and Hand book of pharmaceutical Excipient by  
Raymond  C Rowe., 5th Edition) 
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CROSPOVIDONE 
Synonym: 
 Cross linked povidone 
 Kollido  
 1-vinyl-2-pyrrolidone homopolymer 
 Polyplasdone  
 Polyvinylpolypyrrolidone  
Chemical name : 
 1-Ethylene-2-pyrrolidinone homopolymer 
Functional formula : 
    
Empirical formula: 
 (C6H9NO)n 
Molecular weight: 
 >1000 000 
Functional category: 
 Tablet disintegrant. 
CHAPTER -VII                                                                         EXCIPIENT PROFILE 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI-20  71 
 
Application in pharmaceutical formulation: 
 Tablet disintergrant and dissolution agent. 
 Solubility enhancer for poorly soluble drug  
Description: 
 Crospovidone is a white-creamy white 
 Free flowing 
 Practically tasteless 
 Hygroscopic powder 
Melting Point: 
 150OC 
Stability and Storage condition: 
 Crospovidone is hygroscopic 
 It should be stored in an airtight container in a cool, dry place. 
Incompatibilities: 
 Crospovidone is compatible with most organic and inorganic 
pharmaceutical ingredients. 
 When exposed to a high water level . 
 Crospovidone may form molecular adduct with some materials. 
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Handling Precautions: 
 Observe normal precaution appropriate to the circumstances and quantity 
of material handled. 
 Eye protection gloves and a dust mask are recommended  
( Hand  book of Pharmaceutical Excipients by Raymond C Rowe 5th 
Edition.) 
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TALC 
Synonym: 
  Altalc 
  Hydrous magnesium calcium silicate 
  Hydrous magnesium silicate 
Chemical name: 
  Talc 
  Purified talc 
  Talcum 
Empirical Formula: 
 Talc is purified, hydrated, magnesium silicate. 
  Mg6 ((Si2O5)4(OH) 4) 
  It may contain small variable amounts of silicate and iron. 
Molecular weight: 
 379.27 
Structural Formula: 
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Functional Category : 
 Anticaking agent 
 Glidant 
 Diluent 
 Lubricant 
Application in pharmaceutical formulation: 
 Talc is widely used in solid dosage formulations. 
 Lubricant and Glidant. (1.0-10.0) 
 Diluents in tablet and capsule. (5.0-30) 
 It is widely used as a dissolution retardant in the development of controlled-
release products. 
 Talc is novel powder coating for extended release pellets and as an 
adsorbent. 
 It is used as a dusting powder. (concentration 90.0-99.0) 
 It is used to clarify liquids and is used in cosmetics and food products. 
 It is used in baby powder. 
Description: 
 Talc is very fine, white to grey-white, odourless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to touch and 
free from grittiness. 
Melting Point: 
 800oC 
CHAPTER -VII                                                                         EXCIPIENT PROFILE 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI-20  75 
 
Solubility: 
 Practically insoluble in organic solvent, water and in dilute acids & alkalis. 
Stability and Storage condition: 
 Talc is a stable material and may be sterilized by heating at 160oC for not 
less than one  
hour. 
 It may also be sterilized by exposure to ethylene oxide or gamma radiation. 
 Talc should be stored in well closed container in a cool, dry place. 
Incompatibilities: 
 Incompatible with quaternary ammonium compounds. 
Handling Precautions: 
 Talc is irritant if inhaled and prolonged exposure may cause 
pneumoconiosis. 
 In the UK, the occupational exposure limit for talc is long-term (8 hour 
TWA). Eye 
protection, gloves and respirator are recommended. 
( Hand book of  Pharmaceutical Excipients by Raymond C Rowe.,5th 
Edition) 
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MAGNESIUM STEARATE 
Synonym: 
 Magnesium octadecanoate 
 Octadecanoic acid 
 Magnesium salt 
 Stearic acid 
 Magnesium salt 
Chemical Name: 
 Octadecanoic acid magnesium salt (557-04-0) 
Empirical Formula: 
 Magnesium stearate as a compound of magnesium with a mixture of solid organic 
acids that consists of variable proportions of magnesium stearate and magnesium 
palmitate. 
 Magnesium stearate : C36H20MgO4 
 Magnesium palmitate : C32H62MgO4 
Molecular weight: 
 591.34 
Structural Formula: 
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Functional Category: 
 Tablet and capsule lubricant. 
Application in pharmaceutical Formulation: 
 It is widely used in cosmetics, foods and pharmaceutical formulations.  
  It is used as a lubricant in capsule and tablet manufacture at 
concentrations 0.25% and 5.0% w/w. 
Description : 
 Magnesium Stearate is a very fine, light white, precipitated or milled, 
impalpable 
powder of low density, having a faint odour of stearic acid and a 
characteristic taste. 
  The powder is greasy to touch and readily adheres to the skin 
Melting Point: 
 117-150OC 
Solubility: 
 Slightly soluble in warm benzene and warm ethanol. 
 Practically insoluble in ethanol and water. 
Stability and Storage condition: 
 Magnesium stearate is stable and should be stored in well closed container 
in a cool, dry place. 
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Incompatibilities: 
 Incompatible with strong acids, alkalis and iron salts. 
 Magnesium stearate cannot be used with aspirin, some vitamin and most alkaloidal 
salts. 
Handling Precautions: 
 Eye protection and gloves are recommended. 
 Excessive inhalation of magnesium stearate dust may cause upper 
respiratory tract discomfort, coughing and choking. 
( Hand book of Pharmaceutical Excipients by Raymond C 
Rowe.,5thEdition). 
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CHAPTER –VIII 
EXPERIMENTAL DETAILS 
1.PREPARATION OF STANDARD CALIBRATION CURVE 
 a) Determination of λ max 
 Pioglitazone hydrochloride (10mg) was weighed accurately and transferred in 10 
ml volumetric flask. It was dissolved in methanol and filtered it. Then filtered solution 
diluted up to mark with phosphate buffer (pH 7.4). The final solution contained 1000 μg 
of Pioglitazone per ml of the solution. The solution (1ml) was diluted further to 10 ml 
with the same solvent. The final solution contained 100 μg of pioglitazone per ml of the 
solution as a stock solution. The resultant solution is scanned in the range of (200-
400nm) by Ultra visible Spectrophotometer (UV-1700 Shimadzu corporation, Japan) to 
get absorption maximum (λ max)   (Pragati Shakya* and Kuldeep Singh., 2010)  
b) Preparation of Calibration curve 
 From the above prepared stock solution, different  concentration  (5 to 25μg/ml) 
solutions are prepared using  distilled  water. The absorbances of these solutions  are 
measured   at   λmax  (234nm)   by  UV-  spectrophotometer (UV-1700  Shimadzu 
Corporation, Japan). A standard curve is plotted using concentration on X axis and  the 
absorbance obtained on Y-axis. 
2. SOLUBILITY STUDIES : 
 For the selection of best non volatile solvents solubility studies are used, in this 
procedure, pure drug was dissolved in different non volatile solvents (propylene glycol, 
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Tween 80 and polyethylene glycol 400) and distilled water. Excess amount of pure drug 
was adding to the above solvents. From this obtained saturation solution were shaking 
on the rotary shaker for 48 hours at 250C under constant vibration. After  this  period   
the solutions are filtered, diluted and analysed by UV Spectrophotometer. Three 
determinations are carried out for each sample to calculate the solubility of Pioglitazone 
hydrochloride  (Jyothi Penta et.al., 2014) 
3.PREFORMULATION (COMPATIBILITY) STUDIES : 
        The compatibility studies are carried out by Infrared spectroscopy (IR) 
 in order to evaluate the drug polymer interaction.   
a) Fourier Transform Infrared Spectroscopic studies (FTIR):  
       FTIR spectroscopy helps to determine any chemical interaction between drug and 
excipients used in the formulation. FTIR spectra of pure Pioglitazone and physical 
mixtures were obtained using Shimadzu, Japan. Samples are prepared in KBr disks 
(2mg sample in 200mg KBr).spectrophotometer in the range of 4000-400 cm-1  
( J.Padmapreetha et al.,2016) 
4. FLOWABLE LIQUID-RETENTION POTENTIAL (Φ-VALUE) OF THE 
EXCIPIENTS (AVICEL PH 102 AND AEROSIL 200) 
a) Determination of the angle of slide 
The  angle of slide carrier and coating material (10 gm of Avicel PH 102 and 
Aerosil 200) is measured as follows  .  
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Determination of the angle of the slide is done by weighing the required amount 
of carrier material and placed at one end of a metal plate with a polished surface. The 
end is radually raised till the plate becomes angular to the horizontal at which powder is 
about to slide. This angle is known as the angle of the slide. Angle of 33º is regarded as 
optimum (Utsav et. al.2013) 
    b) Determination of flowable liquid-retention potential (φ-value) 
 The term "flowable liquid-retential potential" (Φ-value) of a powder material 
describes its ability to retain a specific amount of liquid while maintaining good flow 
properties. The Φ-value is defined as the maximum weight of liquid that can be retained 
perunit weight of the powder material in order to produce an acceptably flowing 
liquid/powder admixture 
 The Φ values are calculated according to the equation 
  Φ value = weight of the liquid / weight of solid 
The Φ-values are plotted graphically against the corresponding angles of slide 
(h). The Φ-value corresponding to an angle of slide of 33° represented the 
flowableliquid-retention potential of excipients.  
The Φ-value for Avicel PH 102 and Aerosil 200 is reported in the table below and 
hence there is no need to determine it practically (Amal Ali Elkordy et al., 2013 and Dina 
Louis et al., 2008) 
Table 1 : Φ–values for carrier material and coating material  
(Spireas et al., 1998 and Abdul Hasan Sathali A. and Deepa C. et al., 2013) 
 CHAPTER VIII                                                                  EXPERIMENTAL PROTOCOLS 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI-20  70 
 
Non volatile liquid  
vehicle 
Φ–values for carrier 
material (Avicel PH 102) 
Φ–values for coating 
material (Aerosil 200) 
Propylene glycol 0.16 3.31 
Poly ethylene glycol 400 0.005 3.26 
Tween 80 0.003 3.95 
Cremophor EL  0.18 0.80 
Capryol 90 0.16 0.40 
These values are used for the preparation of liquisolid tablets. 
5.PROCEDURE FOR PREPARATION OF LIQUISOLID SYSTEM : 
 Several Pioglitazone  hydrochloride  liquisolid formulation are prepared in the 
batches of 60 tablets at ratio of (1:1) Drug : liquid vehicles. Each formulation contains 
avicel PH102 as carrier and aerosil 200 as coating material, at carrier /coat ratio (R 
value) of 5,10,15 and 20. The appropriate amounts coating material,used for each 
formulation depend upon Lf of that formulation. The  ΦCa and ΦC0 values for each 
particular liquid vehicle are used to calculate Lf [ Eq-(1)] of that respective liquid vehicle. 
Onec the liquid load factor (Lf) and amount of liquid medication (W) are determined 
amount of carrier (Q) and coating (q) can be calculated by rearranging Eq-(2) and (3) 
Lf = ΦCa + ΦC0 × 1/R                  (1) 
Lf = W/Q                                 (2) 
R = Q/q                                  (3) 
The drug-vehicle liquid system is produced by mixing Pioglitazone hydrochloride 
(30mg/tablet) in non-volatile liquid vehicle using a mortar and pestle. To this liquid 
medication, the calculated amount of the carrier (Avicel PH102) is added by continuous 
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mixing in the mortar. Then the coating material (Aerosil 200) is carefully added and 
mixed until mortar contents start to look like dry powder. In the last stage of the 
preparation, a 5% (w/w) crospovidone as a super disintegrant and 0.75% (w/w) of 
magnesium stearate as a lubricant are added and mixed. All liquisolid preparations are 
compacted into tablets using a multi punch tablet machine (Fludi pack, Ahmedabad) 
having 10mm flat punch. The applied compression force is different from one 
formulation to another formulation depending on the weight of the tablet and the 
preparation (P.B.Dalvi et al.,2014, Dinesh M. Pardhi et al., 2010 and Spiro Spireas et 
al., 1998). 
6.PREPARATION OF DIRECTLY COMPRESSED TABLETS : 
For comparison conventional Pioglitazone hydrochloride (30mg/tablet) are 
prepared by mixing all tablet excipients, except non-volatile liquid vehicle compressed 
into tablets (Amal Ali Elkordy et al., 2012 and Spiro Spireas et al., 1998). 
Table 2:  Composition of directly compressed tablets 
S.No 
Ingredients 
Quantity for one tablet 
(mg) 
1. Pioglitazone  30 
2. Tween 80 30 
3. Avicel PH 102 150 
4. Aerosil 200 15 
5. Crospovidone  11.25 
6. Magnesium stearate  1.77 
7. Talc  2.3 
       Total weight = 240.32mg 
7. PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
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a) Angle of repose 
  The angle of repose was determined by using fixed funnel method. The powder 
is poured from a funnel onto a horizontal surface, it will form a cone. The angle between 
the sides of the cone and the horizontal is referred to as the angle of repose. The angle 
is a measure of the cohesiveness of the powder, as it represents the point at which the 
interparticle attraction exceeds the gravitational pull on a particle. A free-flowing powder 
will form a cone with shallow sides, and hence a low angle of repose, while a cohesive 
powder will form a cone with steeper sides. The angle of repose was determined by 
substituting the values of the base radius ‘r' and height of the pile ‘h’ in the following 
equation.( Monali kalbhor et al .,2017) 
      
Here, h = Height of pile 
r = Radius of pile 
θ = Angle of repose 
Table 3: Limits for angle of repose  
          ANGLE OF REPOSE      POWDER FLOW 
                      <250   Excellent  
                      25-300   Good  
                      30-400   Passable  
                        >400    Very poor 
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b) Bulk density        
         Bulk density is the ratio between given mass of powder and its bulk volume. Bulk    
density is carried out in triplicate. Bulk density measurements are carried by placing 
fixed weight of powder in graduated cylinder and volume occupied is measured and 
initial bulk density is calculated. It is expressed in gm/ml. Bulk density is calculated by 
using following formula (Kamalakanan V. et al., 2012 and Pradeep Yala et al., 2012) 
 
c) Tapped density 
       Tapped density is the ratio of weight of dry powder to its tapped volume. The 
weighed quantity of dry powder was taken is a graduated cylinder. The cylinder was 
placed on the tap density tester (M/s. Inco) and subjected to 100 taps. The volume of 
powdered bed is measured. The tapping is continued until the difference of last two 
volume measurement is zero.( Srinivas Lankalapalli et. al.2014) 
     
d) Carr’s Index 
          The Compressibility Index (Carr’s Index) is a measure of the propensity of a 
powder to be compressed. It is determined from the bulk and tapped densities. In 
theory, the less compressible a material the more flowable it is. As such, it measures 
the relative importance of interparticulate interactions. In a free-flowing powder, such 
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interactions are generally less significant and the bulk and tapped densities will be 
closer in value.For poor flowing materials, there are frequently greater interparticle 
interactions, and a greater difference between the bulk and tapped densities will be 
observed. These differences are reflected in the Compressibility Index which is 
calculated using the following equation. (Manish gore et al.,2014) 
  
The smaller value of the CI%,the superior the flow properties of the powder 
   Table 4 : Values of Carr’s Index  
CARR’S INDEX TYPE OF FLOW 
5-15 % Excellent 
15-25% Good 
> 25% Poor 
 
e) Hausner’s Ratio 
Hauser’s ratio is an important character to determine the flow property of powder 
and Granules. This can be calculated by the following formula. 
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Values less than 1.25 indicate good flow (=20% carr), and greater than 1.25 
indicates poor flow (=33% carr). Between 1.25 and 1.5, added glidant normally 
improves flow (Trinadharao et al.,2015 and Devendra Revanand Rane et al., 2012 ). 
f) Drug content 
The Powder blend containing 10 mg equivalent of drug weighed and dissolved in 
methanol, then the volume is made upto 100ml with distilled water. From the above 
solution, 10 ml is taken and diluted with distilled water. The absorbance of resulting 
solution is measured at 234 nm using UV spectrophotometer (Shimadzu UV-1700 
pharma spec, Japan) and the drug content is estimated. 
8. POSTCOMPRESSIONAL EVALUATION OF LIQUISOLID TABLETS 
a) General appearance 
The formulated tablets are evaluated for general appearance such as colour, 
shape and appearance (Prasanth Sai R.V et al., 2011). 
       b) Thickness 
        Three tablets are randomly selected from each formulations and thickness is 
measured individually by vernier caliper. It is expressed in millimeter (mm) and average 
is calculated. (Amit modi et al., 2012). 
b) Hardness 
         Hardness is defined as the "force required to break a tablet in the diametric 
compression test." Hardness is hence, also termed as the tablet crushing strength. The 
resistance of tablets to breakage under conditions of storage, transportation or handling 
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before usage depends on its hardness. Tablet hardness was measured with Pfizer 
tester. The tablet was held between a fixed and moving jaw. The scale was adjusted to 
zero and load was gradually increased until the tablet fractured. The value of the load at 
that point gives a measure of the hardness of the tablet. Hardness was expressed in 
kg/cm2. Hardness was reported in Table (Monali kalbhor et al.2017) 
c) Weight variation 
        The test was performed as per USP by weighing 20 tablets individually on electric 
balance, calculating the averageweight, and comparing the individual tablet weight to 
the average weight.(srinivasarao et al.,2015) 
Table 5 :Limits for weight variation test 
AVERAGE 
WEIGHT 
MAXIMUM % DIFFERENCE       
ALLOWED 
130 mg or less            ± 10% 
130 mg to 324 mg            ± 7.5% 
More then 324 mg            ±  5 % 
   
d) Friability Test 
This test is performed to evaluate the ability of tablets to withstand abrasion in 
packing, handling and transporting. Friability generally reflects poor cohesion of tablet 
ingredients. The initial weight of 10 tablets is taken and these are placed in the friability, 
which is consist of a circular plastic chamber, divided into 2-3 compartments. The 
chamber rotating at 25 rpm for 4min and drops the tablets by a distance of 15cm and 
 CHAPTER VIII                                                                  EXPERIMENTAL PROTOCOLS 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI-20  77 
 
gives 100 revolutions. After that, the tablets are weighed once again. The difference in 
the weight is noted and expressed as the percentage. It should be preferably below 
1.0%. Friability was reported in Table ( Pooja et al.,2015 and Anand Kishore et al., 
2011).  
  
Where, 
W1= weight of tablets before test, 
W2 = weight of tablets after test 
e) Drug content 
      The total amount of drug present in the liquisolid formulation is evaluated using UV 
spectrophotometric analysis. Approximately weighed quantity of 10mg equivalent of 
drug is taken from liquisolid formulation which is dissolved in 10ml of methanol and the 
volume is made upto 100ml with distilled water. From the above solution, 10 ml is taken 
and diluted with distilled water. The absorbance of resulting solution (10μg/ml) is 
measured at 234 nm using spectrophotometer (shimadzu UV- 1700 pharma spec, 
Japan) and the drug content is calculated from the standard curve using the formula 
(Srinivas Vaskula et al., 2012).  
Drug content =   
𝑆𝑎𝑚𝑏𝑙𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
×100 
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f) Disintegration test 
            Disintegration is defined as that state in which no residue of the tablet or capsule 
remains on the screen of the apparatus. The disintegration time of the liquisolid tablets 
is determined using disintegration test apparatus. Introduce one tablet into each tube 
and floating of the tablets can be prevented by placing a perforated plastic disc to each 
tube. Suspend the basket rack in the beaker containing the 900 ml of distilled water at 
37 oC and move the basket containing the tablets up and down through a distance   of 
5-6 cm at a frequency of 28-32 cycles per minutes and the disintegration time for each 
formulations is noted (Indian Pharmacopoeia.,1996. Page no: A-80 to A-81). 
Disintegration time 
a) Uncoated tablets: 5- 30 minutes 
b) Coated tablets: 1-2 hours 
9. IN VITRO RELEASE STUDIES 
             In vitro release studies is performed by using USP type II Paddle dissolution 
apparatus in 900 ml of Phosphate buffer pH 7.4 maintained at 37° C ± 0.5° C and 
rotation speed of 50 rpm. Samples (5 ml) are withdrawn at suitable time intervals (5, 10, 
15,20, 25, 30, 45, 60 minutes) and filtered through whatman filter paper. Sink conditions 
are maintained throughout the study. The withdrawn samples are analyzed by UVvisible 
spectrophotometer (Shimadzu UV-1700 pharma spec, Japan) at λ max of 234nm. The 
studies are done in triplicate (Dinesh M. Pardhi et al., 2010 and www.fda.gov) 
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10. POWDER X-RAY DIFFRACTION STUDIES 
       Powder X-ray diffraction pattern of Pioglitazone hydrochloriude, Avicel PH102, 
Aerosil 200 and liquisolid formulation (Best formulation) are studied using X-ray 
diffractometer (XRD-462, Digaku, Japan) with CuKα radiation. Voltage and current are 
set 40 kV and 30 mA respectively. All pattern scanned over range 3-50o 2θ angle with a 
scan speed of 20/min (Jahnavi N et al., 2013). 
11. ASSESSMENT AND COMPARISON OF DRUG DISSOLUTION RATES   
           The dissolution rate of pioglitazone hydrochloride is the amount of drug ( in µg) 
dissolved per minute by each tablet formulation  during first 10 min is calculated by the 
following  equation (Shashidher Burra et al., 2011 and Spireas et al., 1998) 
                     DR =
(𝑀×𝐷)
1000
  
Where, 
M = Total amount of pure drug in each tablet (in μg) 
D = Percentage of drug dissolved in the first 10 minutes 
12. SELECTION AND EVALUATION OF BEST FORMULATION 
The best formulation is selected depending on the results obtained from 
solubility studies in various non-volatile liquid vehicles and in vitro release studies  
a) Comparison with directly compressed tablets 
   The invitro release of best formulation is compared with directly compressed 
tablets are prepared by mixing all tablet excipients, except non-volatile liquid 
vehicle (Amal Ali Elkordy et al., 2012 and Spiro Spireas et al., 1998) 
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b) Infrared spectroscopic studies for best formulation 
      Liquisolid formulation (Best formulation) is subjected to infrared Spectroscopic   
studies as per the procedure already discussed in compatibility studies. 
c) Differential Scanning Colorimetric (DSC) studies for best formulation 
      DSC was performed using Shimadzu differential scanning calorimeter Mettler, 
in order to assess the thermotropic properties and thermal behaviour of the pure drug , 
and the liquisolid formulation (Best formulation). About 5 mg of the sample were 
sealed in the aluminium pans and heated at the rate of 10°C/min, covering a 
temperature range of 30°C to 300°C.( Jabbar et al.2013)  
d) RELEASE KINETICS STUDIES 
1. Zero – order model: Drug dissolution from dosage forms that do not disaggregate 
and  release the drug slowly can be represented by the equation: 
                                                     Qt = Q0 + K0t 
Where, 
Qt is the amount of drug dissolved in time t, 
Q0 is the initial amount of drug in the solution, 
K0 is the zero order release constant and 
“t” is time in hours. 
Expressed in units of concentration/time. 
Graph: X- axis is time in hours and Y- axis is % cumulative drug release. 
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2. First order model: The release of the drug which followed first order kinetics can 
be expressed by the equation: 
observed in final formulation, which indicates that the pioglitazone  was molecularly 
dispersed and in an amorphous form (Sanjeev Gubbi et al., 2009 and Abdul Hasan 
Sathali A. and Deepa C. et al., 2013) 
                                           log Qt = log Q0 + Kt / 2.303 
Where, 
Q0 is the initial concentration of drug,  
Qt is cumulative amount of drug released per unit surface area,  
k is the first order rate constant and “t” is the time. 
Graph: X- axis is time in hours and Y- axis is log % cumulative drug release. 
3. Hixon Crowell model: Hixson and Crowell (1931) recognized that the particles 
regular area is proportional to the cube root of its volume. The equation describes the 
release from systems where there is a change in surface area and diameter of 
particles. They derived the equation: 
                                                W01/3 - W1/3 = KHC *t 
Where, 
W0 is the initial weight of particle,  
W is the weight of particle, KHC is Hixon Crowell release rate constant and “t” is time. 
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4. Higuchi model:  
Higuchi model describes the drug release from several type of matrices initially 
conceived for planar systems, then extended to different geometrics and porous 
systems. It was derived by higuchi in 1961. For higuchi release kinetics equation  
                                                      Q = KH t 0.  
Where, 
Q is amount of drug released per unit surface area of the dosage form 
KH is Higuchi release rate constant and 
 “t” is time. 
5. Korsmeyer – Peppas model: Koresmeyer derived a simple relationship which 
describes drug release from a polymeric system. To find out the mechanism of drug 
release, first 60% drug release data was fitted in Koresmeyer – Peppas model 
equation, 
                                                    (Mt/M) = Km tn 
where, 
Mt is amount of drug released at time t,M is total amount of drug in dosage form,Km is 
kinetic constant,n is diffusion and release exponent and t is time in hours 
    d)Stability studies 
         The best formulation of three batches is stored at 40° C ± 2°C and relative RH 
75% ± 5% for two months. The best formulation is evaluated using dissolution test, drug 
content, physical appearance, hardness and thickness. The above tests of best 
formulations are compared with those of freshly prepared tablets. 
 (Prasanth Sai R.V et al., 2011 and Amit Modi et  al., 2012). 
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CHAPTER-IX 
RESULTS AND DISCUSSION 
1.PREPARATION OF STANDARD CALIBRATION CURVE 
The λmax of Pioglitazone hydrochloride was determined by scanning the 
(10μg/ml) solution of drug in phosphate buffer Ph 7.4 by UV-spectrophotometer and it 
was found to be 234nm((Pragati Shakya* and Kuldeep Singh., 2010 ) (Figure 5). The 
absorbance of the solution (5-25 μg/ml) was measured in UV-spectrophotometer at 234 
nm. The linear correlation coefficient was found to be γ = 0.9998. The results were 
shown in Table 6and the calibration graph of Pioglitazone hydrochloride was shown in 
Figure 6. 
2. SOLUBILITY STUDIES 
The solubility of pioglitazone hydrochloride was determined in various non-
volatile liquid vehicles such as Propylene glycol (PG), Polyethylene glycol (PEG 400), 
Tween 80, Capryol 90 and in distilled water shown in Table 7 and Figure 7. From the 
results, it was observed that the solubility of drug in Tween 80 was higher when 
compared with other liquid vehicles which may be due to the high viscosity and HLB 
value  Prasanna et al., 2015)  
3. PREFORMULATION (COMPATIBILITY) STUDIES 
a) Infrared Spectroscopic Studies 
Infrared (IR) spectroscopic studies were carried out to confirm the compatibility 
between drug and excipients used for the preparation of liquisolid tablets. The IR 
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studies were performed for pioglitazone hydrochloride (pure drug), non-volatile liquid 
vehicle, microcrystalline cellulose, aerosil 200 and physical mixture of drug and 
excipients. The spectra studied at 4000cm-1 to 400 cm-1 were shown in Figure 8  
 The principal peaks for pure drug were observed at wave numbers 3415.93 cm-1, 
3363.96 cm-1, 1639.49 cm-1, 1608.63 cm-1, 1294.24 cm-1, 1176.58 cm-1, Further in the 
physical mixtures, all the above characteristics peaks of the drug appear in the 
spectrum, which indicated that there was no interaction between the drug and polymers 
in the physical mixture  
Further in the physical mixtures, all the above characteristics peaks of the pure 
drug appear in the spectrum, which indicated that there was no interaction between the 
drug and polymers in the physical mixture. 
4. FLOWABLE LIQUID-RETENTION POTENTIAL (Φ-VALUE) FOR 
EXCIPIENTS 
Angle of slide was used to determine the Φ-value for the excipients (which are 
needed for calculation of the Lf). The ΦCA-value (carrier) and ΦCO-value (coating 
material) decided the appropriate quantities of carrier and coating materials required to 
convert a given amount of liquid medication into a dry-looking, free flowing and readily 
compressible liquisolid formulation. Flowable liquid-retention potential values for 
excipients were taken from literature (Spireas et al., 1998)  
The flowable liquid- retention potential (Φ-value) for Avicel PH 102 carrier in 
  Propylene glycol was approximately        0.16 
 Polyethylene glycol was approximately   0.005 
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 Tween 80 was approximately                  0.003 
  The flowable liquid- retention potential (Φ-value) for Aerosil 200  coating material in 
 Propylene glycol was approximately        3.31 
 Polyethylene glycol was approximately   3.26 
 Tween 80 was approximately                   3.95 
The relatively high Φ -value is advantageous as it results in smaller sizes of the 
tablets. The above values were used to formulate liquisolid tablets of Pioglitazone 
hydrochloride (Amal Ali Elkordy et al., 2013). 
5. PROCEDURE FOR PREPARATION OF LIQUISOLID POWDER 
 Liquisolid powder of pioglitazone hydrochloride  were prepared using different  
non-volatile liquid vehicle( Propylene glycol,Polyethylene glycol 400,Tween 80) at  ratio 
of (1:1) drug: liquid vehicles. The microcrystalline cellulose (Avicel PH102) was used as 
a carrier and silica (Aerosil 200) as coating material. Finally 5% (w/w) crospovidone as a 
super disintegrant and 0.75% (w/w) of magnesium stearate as a lubricant were added 
and mixed. All liquisolid preparations were compacted into tablets using a multi punch 
tablet machine (Fluid pack, Ahmedabad) having 10mm flat punch. The compositions of 
all the formulations were given in Table.8 Twelve formulations (F1- F12) were 
prepared.(Prasanna MV et al.,2015) 
6. PREPARATION OF DIRECTLY COMPRESSED TABLETS 
    A conventional formulation of pioglitazone hydrochloride were prepared by using drug 
(Pioglitazone hydrochloride),Microcrystalline cellulose (Avicel PH 102), Silica (Aerosil 
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200) and sodium starch glycolate, without addition of any non-volatile liquid vehicles. 
The composition of the formulation was given in Table 9 
7. PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
  Powder flow is a critical character that might affect uniformity of the tablet weight. 
Therefore, the flow properties of the powder blend of all liquisolid formulations were 
determined in order to calculate that the amount of carrier and coating materials were 
required to maintain acceptable flow and compaction properties. The powder blend of 
all formulations was evaluated for precompression parameters such as angle of repose, 
bulk density, true density, carr’s index, Hausner’s ratio and drug content 
a) Angle of Repose 
 The angle of repose is a characteristic of the internal friction or cohesion of the 
particles, the value will be low, if the powder is non-cohesive and high if the powder is 
cohesive. All the prepared formulations were in the ranges from 26’.24O to 33.39O, 
which indicates the good flow properties of liquisolid powder. The results of angle of 
repose of all formulations were shown in Table 10 and Figure 10 
b) Bulk density 
    Bulk density was used to measure the flow properties of the powder. The bulk 
density of the powder blend was in the range of 0.206 gm/ml to 0.855 gm/ml. The  
results of bulk density for all the formulations were shown in Table 10 and Figure 11 
b) Tapped density 
  The tapped density of the powder blend was in the range of 0.250 gm/ml to 
gm/ml. The results of bulk density for all the formulations were shown in Table 10 and 
Figure 12 
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c) Carr’s Index (CI) 
  Determination of carr’s index, the ratio of bulk and tapped density, was used to 
measure the flow property of all liquisolid formulations. The decrease the value of the 
CI% would indicate the better flow properties of the powder. The carr’s index of the all 
formulations was found to be in range of 9.55% to 14.56%. It was less than 25%, which 
indicates that the powder blend have required flow property for compression of tablets. 
The results of carr’s index of all formulations were shown in Table 10 and Figure 13  
b) Hausner’s Ratio 
 The Hausner’s ratio of all the formulations was found to be in range of 1.01 to 
1.19, which indicates better flow property of the powder blend. The results were shown 
in Table 10 and Figure 14  
c) Drug content 
The percentage drug content for all formulations was found to be in the range of  
96.12% to 99.88%, ensured the uniformity of the drug content. The results indicated all 
the formulations were within the limits as per IP (Limit: not less than 85% and not more 
than 115%). The results were shown in Table 13 and Figure 15. 
All the above precompressional evaluations were done for directly compressed 
tablets and they were within the limit (Table 11). 
8. POSTCOMPRESSIONAL EVALUATION OF LIQUISOLID TABLETS 
Tablets of different formulations were evaluated for the postcompressional 
parameters such as general appearance, weight variation, hardness, thickness, 
friability, disintegration time and drug content for tablets. 
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a) General appearance 
The formulated tablets were white in colour, biconvex and round shape. All the 
tablets were elegant in appearance. The results were shown in the Table 12. 
b) Thickness 
The thickness of all the tablet formulations was used to determine the uniformity 
of size and shape of the tablets. All the prepared tablet formulations were measured by 
vernier caliper and were found to be in the range of 2.45 to 5.2mm. The results 
indicated that all the formulations had uniform size and shape. The results were shown 
in Table 12. 
c) Hardness 
Hardness of tablet was used to determine the resistance to withstand mechanical 
shakes of handling in manufacture and packing. All the prepared tablets were 
determined using Monsanto hardness tester. The hardness of all the formulations was 
found to be 4 to 5 Kg/cm2, which indicates that all the tablet formulations had good 
mechanical strength. The results of all the formulations were shown in Table 12. 
d) Weight variation  
The weight was used to ensure the uniformity of the tablet in all formulations. All 
the formulation tablets passes the weight variations within the acceptable limits as per 
IP.the results were shown in Table 12. 
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e) Friability test 
The friability of tablets was determined using Roche friabilator and used to 
determine the mechanical strength of tablets.the percentage friability of all the tablet 
formulation was found to be in the range of 0.20 to 0.64 %. It was less then 1% the 
results indicated that all the tablets formulation had a good mechanical resistance of 
tablets. The results were shown in Table 12 
f) Drug content 
The drug content was used to determine the uniform amount of active ingredients 
presenty in all the formulations. The drug content was found to be in the range of 
96.12% to 99.88% which indicates all the formulations were within the acceptable limits 
as per IP (Limits not less then 85% and not more then 115%) The results were shown in 
Table 11 
d) Disintegration test 
The disintegration time of all the tablet formulations was determined using 
disintegration test apparatus. All the prepared tablet formulations were in between 3 min 
30 sec to 8 min 7 sec. it was lesser then 15 minutes. Which indicates all the  
    All the above postcompressional evaluations were done for directly compressed 
tablets and they were within the limit.(Table 12 ) 
9. INVITRO RELEASE STUDIES 
In vitro dissolution studies were carried out by USP type II method by using 
Phosphate buffer pH 7.4 as a medium. The samples were taken at an interval of 10min 
absorbance was measured in UV spectrophotometer at 234nm. 
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Two formulation parameters such as effect of drug concentration in the liquid 
medication (ratio of drug and liquid vehicle) and effect of carrier/coating ratio (R value) 
that would affect the drug dissolution rate in immediate release liquisolid tablets were 
investigated. 
The results of in vitro release studies from liquisolid formulations shown in 
(Table 15a,15b and Figure 16a to 16d) 
Formulations F1, F2, F3, and F4 were prepared with 1:1,(ratio of drug and 
Propylene glycol) 5:1, 10:1, 15:1 and 20:1 (ratio of MCC & Aerosil 200) showed the 
cumulative % of drug release  95.67%,93.79%,92.01%, and 94.10% . 
             Formulations F5, F6, F7, and F8 were prepared with 1:1,(ratio of drug and 
Polyethylene glycol-400) 5:1, 10:1, 15:1 and 20:1 (ratio of MCC & Aerosil 200) showed 
the cumulative % of drug release 94.00%,93.27%,95.81% and 96.23% 
Formulations F9, F10, F11, and F12 were prepared with 1:1,(ratio of drug and 
Tween 80) 5:1, 10:1, 15:1 and 20:1 (ratio of MCC & Aerosil 200) showed the cumulative 
% of drug release 95.36%,94.94% 97.07% and 98.74%. The formulation which showed 
highest release among all the formulations was F12 (98.74%) 
F12>F11>F8>F7>F1>F9>F10>F4>F5>F2>F6>F3 
     From the above results, it was observed that the drug release was faster for 
formulation F12, containing the ratio 1:1 (drug:Tween 80). The enhanced drug 
dissolution rate may be mainly attributed to the fact that this poorly water-soluble drug is 
already in solution in Tween 80, while at the same time, it is carried by the powder 
particles (microcrystalline cellulose-silica) of liquid vehicle. Thus, its release is 
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accelerate due to its markedly increased wettability and surface availability to the 
dissolution medium. 
Microcrystalline cellulose and Aerosil 200 were used as carrier and coating 
materials, respectively in prepared formulations. The effect of carrier and coating 
material ratio (R-value) on the drug dissolution were investigated. Two R-value of 
5,10,15 and 20 were studied. Generally, the higher R-value showed higher drug 
dissolution than the lower R-value. 
It was observed that formulation F12 with higher R-value showed a higher drug 
release than the formulation with lower R-value. Liquisolid tablets with high Rvalue 
would contain high amount of microcrystalline cellulose (act as disintegrant), low 
amount of Aerosil 200 (hydrophobic in nature that would retard drug release) and low 
liquid load factor. 
The overall results indicated that the prepared immediate release liquisolid tablet 
formulation (F12) at the ratio of 1:1 (drug: Tween 80) and the higher R-value (30) which 
improved the dissolution behavior of drug (Nokhodchi. A et al., 2005). 
Among all the 12 formulations, F12 was selected as a best formulation which had 
the better drug release rate (98.74% at 1hour). Accordingly, this improved drug release 
may result in a higher drug absorption in the gastrointestinal tract and thus, an improved 
oral bioavailability. 
10. POWDER X-RAY DIFFRACTION STUDIES 
Polymorphic changes in the drug are important factor which might affect the 
dissolution rate of drug and in turn bioavailability. So that it is necessary to study the 
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polymorphic changes of pure drug in liquisolid systems. The crystalline nature of drug 
was studied by the characteristic PXRD pattern which showed sharp peaks at 
18o,,20o,28o,and 30o positions. PXRD for pure drug, excipients and liquisolid systems 
were showed in Figure 10a & 10b 
   Liquisolid powder x ray diffraction pattern showed absence of these 
characteristic peaks of drug, which indicated pure drug, was entirely converted into 
amorphous or solubilized from. Theabsence of crystalinity in the liquisolid formulation 
might be due to solubilization ofdrug in liquid vehicle that is possibly absorbed and 
adsorbed on the carrier and coating material. The amorphization or solubilization of 
pure drug may result in an enhancement of dissolution rate (Sanjeev Ragavendra Gubbi 
et al., 2010 and Abdul Hasan Sathali A. and Deepa C. et al., 2013). 
11. ASSESSMENT AND COMPARISON OF DRUG DISSOLUTION RATES 
The concentration of drug and Tween 80 is one of the main factors for the 
formulation of a liquisolid tablets and has considerable effect on the 10 min dissolution 
rate. Dissolution rate increased with an increase in the concentration of Tween 80 due 
to high molecular dispersion states of the drug in the formulations. The results were 
shown in Table 17. The comparison of dissolution rate for pure drug, directly 
compressed tablets and liquisolid formulation were shown in Table 18 and 
Figure 12 
Formulations F1, F2, F3, and F4 were prepared with 1:1, (ratio of drug and 
Propylene glycol) and R-value of 5,10,15 and 20 showed the dissolution rate of 100.60 
μg/min, 97.70 μg/min, 120.48 μg/min, and  124..82 μg/min,  respectively at 10 min. 
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Formulations F5, F6, F7, and F8 were prepared with 1:1, (ratio of drug and 
Polyethylene glycol-400) and R-value of 5,10,15 and 20 showed the dissolution rate of 
127.27 μg/min, 135.24 μg/min, 120.48 μg/min, and  136.34 μg/min, respectively at 10 
min. 
Formulations F9, F10, F11, and F12 were prepared with 1:1, (ratio of drug and 
Tween 80) and R-value of 5,10,15 and 20 showed the dissolution rate of 114.41 μg/min, 
127.91 μg/min, 153.00 μg/min, and  182.27 μg/min,  respectively at 10 min. Among the 
Twelve formulations F12 showed maximum dissolution rate of 182.27 μg/min. 
The dissolution rate of pure drug, directly compressed tablet and liquisolid 
formulation were showed 41.30 μg/min, 95.66μg/min and 182.27 μg/min respectively. 
As it clear from the figure 12, the liquisolid tablets displayed higher dissolution rate than 
those of directly compressed tablet and pure drug. 
 According to the classic dissolution equation: 
       DR = (D/h) S (CS – C) 
The drug dissolution rate (DR) of a drug is directly proportional to its 
concentration gradient (Cs–C) in the stagnant diffusion layer and its surface (S) 
available for dissolution. Cs is the saturation solubility of the drug in the dissolution 
medium and, thus, it is a constant characteristic property related to the drug and 
dissolving liquid involved. Since all of dissolution tests for formulations were done at a 
constant rotational paddle speed (50 rpm) and identical dissolving media, we can 
assume that the thickness (h) of the stagnant diffusion layer and the diffusion coefficient 
(D) of the drug molecules remain almost identical. Therefore, the observed higher 
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dissolution rates of paliperidone from liquisolid tablets are due to the significantly 
increased surface of the molecularly dispersed pioglitazone. In addition, the saturation 
solubility of the drug in the microenvironment (Cs) might be increased in the liquisolid 
systems due to the presence of Tween 80. So, such an increase in Cs, in a larger drug 
concentration gradient, increases the dissolution rate of pioglitazone  according to the 
Noyes Whitney equation (Dinesh M. Pardhi et al., 2010 & Nokhodchi A. et al., 2005). 
12. SELECTION AND EVALUATION OF BEST FORMULATION 
From the above results of characterization F20 was selected as the best formulation. 
             1. Solubility of drug in Tween 80 –   14.124 (mg/10ml) 
2. In vitro release studies     -              98.74% at 60 min 
1. Comparison of dissolution studies of best formulation with pure drug and 
directly compressed tablets 
The in vitro dissolution studies of best formulation (F12) were compared with 
pure drug and directly compressed tablets. The cumulative percentage of drug in 
formulation was found to be 98.74% in 1 hour compared to the pure drug and directly 
compressed tablets whose cumulative percentage drug release was found to be 
22.00% & 42.59% in 1 hour, respectively. Thus the formulation F12 showed higher drug 
release than the pure drug and directly compressed tablets. The results were shown in 
Table 19 and Figure 13. 
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2. Infrared spectroscopic studies 
Infrared spectrum was performed for the liquisolid formulation, the major peaks of 
the drug still shown in the spectrum at 3510.45 cm-1, 3396.64 cm-1 , 2922.16 cm-
1,2358.98 cm-1,1647.21 cm-1, 1560.77 cm-1, 1249.02 cm-1, 1114.86 cm-1, 
1016.49cm-1, 857.73 cm-1 indicated that there was no interaction between the drug 
and polymers in the preparation of liquisolid compacts. The result was shown in Figure 
3. Differential scanning colorimetric studies 
The DSC thermogram of pure drug, excipients and final formulation were shown 
in Figure 9a to 9b. Pure pioglitazone showed a sharp endothermic peak at 193.88°C 
corresponding to its melting temperature 192.13. Such sharp endothermic peak signifies 
that pioglitazone used was in pure crystalline state. Microcrystalline cellulose showed 
sharp endothermic peak at 100.50 °C. The thermal behavior of aerosil 200 did not show 
any sharp endothermic peak and hence, the aerosil 200 was in an almost amorphous 
state. The sharp endothermic peak of pure drug was not 
4. DRUG RELEASE KINETIC MODEL 
    In order to describe the kinetics of the release process of drug in all formulations, 
equations such as zero-order and first- order rate equations were used. Zero order rate 
equation describes the system where the release rate is independent of the 
concentrations of the dissolved species. While the first- order equation describes the 
release from systems where dissolution rate is dependent on the concentration of the 
dissolving species. It is evident from Table 19, and 19B  that the drug release process 
is not zero order in nature. This indicates that the dissolution rate of the drug is not 
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independent of the amount of drug available for dissolution and diffusion from the 
matrix. The dissolution data of all formulations when fitted in accordance with the first 
order equation it is evident that a linear relationship was obtained with ‘r’ (correlation 
coefficient) value close to unity and higher than ‘r’ obtained from zero order equation for 
all formulation (table), showing that the release is an apparent first order process. This 
indicates that the amount of drug released is dependent on the matrix. 
The obtained from invitro dissolution studies were fitted to zero –order, first-order 
and Korsmeyer Peppas equation. The first-order plots were found to be fairly linear as 
indicated by their high regression values. To confirm the exact mechanism of drug 
release, the data were fitted according to Korsmeyer Peppas equation: 
Mt/m∞= k tn 
where mt/m∞ is fraction of drug released, k is kinetic constant, t is release time 
and n is the diffusional exponent for drug release. Peppas stated that the above 
equation could adequately describe the release of solutes from slabs, spheres, 
cylinders and discs, regardless of the release mechanism. The value of ‘n’ gives an 
indication of the release mechanism; when n =1, the release rate is independent of time 
(zero-order) (case II transport), n = 0.5 for Fickian diffusion and when 0.5 < n <1.0, 
diffusion and non-Fickian transport are implicated. Lastly,when n > 1.0 super case II 
transport is apparent. ’n’ is the slope value of log mt/m∞ versus log time curve. Slope 
values (n > 1.0) suggest that the release of cilnidipine from orodispersible tablets 
followed Supercase-II transport suggesting that more than one mechanism may be 
involved in the release kinetics. The results were shown in Figure 19a and 19b.  
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14.Stability studies 
The stability studies were investigated whether the physical chemical parameters 
and dissolution of liquisolid tablets is affected by storage under a 40° C ± 2°C and 75%± 
5% RH. The best formulation of three batches is stored at 40° C ± 2°C and 75%± 5% 
RH for two months. The results showed no significant changes in physical appearance, 
hardness, thickness, drug content and dissolution test of aged tablets compared to the 
fresh liquisolid tablets. This indicates that the liquisolid tablets were stable under these 
storage conditions. The results were shown in Table 20 and Figure 25. 
TABLE  6: CALIBRATION OF PIOGLITAZONE HYDROCHLORIDE  
IN PHOSPHATE BUFFER pH 7.4 
 
S.NO 
 
 
  CONCENTRATION 
         (µg/ml) 
 
ABSORBANCE ± SD* 
     
    1. 
 
5 
   
   0.173 ± 0.03 
     
    2. 
 
10 
 
   0.307 ± 0.06 
     
    3. 
 
15 
 
   0.443 ±0.08 
     
    4. 
 
20 
 
   0.588 ± 0.12 
     
    5. 
 
25 
 
   0.729 ± 0.13 
    
 n=3*        = 0.9998    
  
 
 
 
 
 
 
 
 
 
 
TABLE 7 : DETERMINATION OF SOLUBILITY OF PIOGLITAZONE 
HYDROCHLORIDE  DIFFERENT NON-VOLATILE LIQUID VEHICLES 
 
S.NO 
 
 
  NON-VOLATILE LIQUID       
           VEHICLES 
 
SOLUBILITY (mg/10ml)  
              ±SD* 
 
  1. 
 
PROPYLENE GLYCOL 
 
 
9.201 ± 0.15 
 
  2. 
 
PEG-400 
 
 
8.331 ± 0.14 
 
  3. 
 
TWEEN 80 
 
 
14.124 ± 0.16 
 
  4. 
 
CAPRYOL 90 
 
 
8.657 ± 0.09 
 
  5. 
 
DISTILLED WATER 
 
 
1.204 ± 0.07 
 
n=3* 
PEG 400 = Polyethylene Glycol 400, Tween 80 = Polysorbate, 
CAPRYOL 90 = Propylene Glycol Monocaprylate 
 
 
 
 
 
TABLE 8 : COMPOSITION OF PIOGLITAZONE HYDROCHLORIDE LIQUISOLID TABLET 
Formulation 
Code 
Non- volatile liquid    
vehicle 
 
R 
Active 
Ingredient 
(mg) 
Liquid 
Vehicle 
(mg) 
 
Lf 
Avicel 
PH102 
Q 
(mg 
Aerosil 
200 
q 
(mg) 
Disintegrant 
[Crospovidone] 
(mg) 
Magnesium 
Stearate 
(mg) 
Talc 
(mg) 
 
Total 
Weight 
Of tablet 
(mg) 
 
F1 
 
Propylene glycol 
 
5 
 
30 
 
30 
 
0.822 
 
36.49 
 
3.6 
 
5.3 
 
0.793 
 
1.06 
 
107.24 
 
F2 
 
Propylene glycol 
 
10 
 
30 
 
30 
 
0.491 
 
61.09 
 
6.1 
 
6.75 
 
1.0 
 
1.0 
 
135.94 
 
F3 
 
Propylene glycol 
 
15 
 
30 
 
30 
 
0.380 
 
78.94 
 
7.8 
 
7.75 
 
1.15 
 
1.54 
 
157.18 
 
F4 
 
Propylene glycol 
 
20 
 
30 
 
30 
 
0.325 
 
92.30 
 
9.2 
 
8.07 
 
1.2 
 
1.69 
 
172.59 
 
F5 
Polyethylene 
glycol-   400 
 
5 
 
30 
 
30 
 
0.657 
 
45.66 
 
4.5 
 
5.50 
 
0.86 
 
1.16 
 
117.68 
 
F6 
Polyethylene 
glycol-   400 
 
10 
 
30 
 
30 
 
0.331 
 
90.63 
 
9.6 
 
7.98 
 
1.25 
 
1.68 
 
170.54 
 
F7 
Polyethylene 
glycol-   400 
 
15 
 
30 
 
30 
 
0.222 
 
135.13 
 
13.51 
 
10.43 
 
1.64 
 
2.2 
 
222.91 
 
F8 
Polyethylene 
glycol-   400 
 
20 
 
30 
 
30 
 
0.168 
 
178.57 
 
17.85 
 
12.82 
 
2.0 
 
2.7 
 
273.94 
 
F9 
 
Tween80 
 
5 
 
30 
 
30 
 
0.793 
 
37.83 
 
3.7 
 
5.07 
 
0.79 
 
1.0 
 
108.39 
 
F10 
 
Tween80 
 
10 
 
30 
 
30 
 
0.398 
 
75.37 
 
7.5 
 
7.14 
 
1.12 
 
1.5 
 
152.63 
 
F11 
 
Tween80 
 
15 
 
30 
 
30 
 
0.266 
 
112.78 
 
11.2 
 
9.19 
 
1.44 
 
1.9 
 
196.51 
F12 Tween80 20 30 30 0.200 150 15 11.25 1.77 2.3 240.32 
 
Tween 80 = Polysorbate 80, R= Carrier and coating material ratio, Lf = Liquid load factor, Q=W/Lf(Q=Carrier material and W= Total weight of drug 
and liquid vehicle ), q=Q/R (q=Coating material). 
Table 9: COMPOSITION OF DIRECTLY COMPRESSED TABLETS 
S.No Ingredients 
Quantity for one tablet 
(mg) 
 
1 
Pioglitazone 
hydrochloride 
 
30 
 
2 
 
Avicel PH102 
 
184.12 
 
3 
 
Aerosil  200 
 
17.85 
 
4 
 
Crospovidone 
 
12.82 
 
5 
 
Magnesium stearate 
 
2.0 
 
6 
 
Talc  
 
2.7 
 
Total weight = 249.49mg 
 
 
 
 
 
 
 
 
 
 
TABLE 10: PRECOMPRESSIONAL EVALUATION OF POWER BLEND 
 
Formulation 
code 
Angle of 
repose 
 ± SD* 
Bulk 
density 
(g/ml) ± 
SD* 
Tapped 
density 
(g/ml) ± SD* 
Carr ‘s 
Index 
(%)± SD* 
Hausner ‘s 
ratio 
± SD* 
 
     F1 
 
33.37±1.54 
 
0.802 ±0.05 
 
0.877 ± 0.01 
 
12.16 ± 0.84 
 
1.096 ± 0.05 
 
     F2 
 
32.98±1.83 
 
0.806 ±0.02 
 
0.896 ± 0.02 
 
12.00 ± 1.55 
 
1.112 ± 0.05 
 
     F3 
 
32.96±1.73 
 
0.820 ±0.01 
 
0.935 ± 0.02 
 
11.94 ± 1.77 
 
1.146 ± 0.04 
 
     F4 
 
34.16±1.83 
 
0.832 ±0.01 
 
0.937 ± 0.02 
 
12.34 ± 0.81 
 
1.074 ± 0.01 
 
     F5 
 
31.69±0.67 
 
0.841 ±0.01 
 
0.926 ± 0.02 
 
12.3 ± 0.72 
 
1.099 ± 0.03 
 
     F6 
 
33.15±1.12 
 
0.834 ±0.00 
 
0.912 ± 0.00 
 
9.26 ± 0.94 
 
1.017 ± 0.02 
 
     F7 
 
31.66±1.58 
 
0.816 ±0.01 
 
0.940 ± 0.02 
 
9.55 ± 0.65 
 
1.146 ± 0.03 
 
     F8 
 
32.79±0.47 
 
0.813 ±0.01 
 
0.935 ± 0.02 
 
13.17 ± 1.02 
 
1.192 ± 0.04 
 
     F9 
 
29.55±0.76 
 
0.817 ±0.00 
 
0.921 ± 0.01 
 
9.96 ± 0.92 
 
1.055 ± 0.02 
 
     F10 
 
31.27±1.63 
 
0.806 ±0.01 
 
0.939 ± 0.02 
 
13.8 ± 0.52 
 
1.159 ± 0.03 
 
     F11 
 
28.81±0.52 
 
0.832 ±0.01 
 
0.925 ± 0.00 
 
12.23 ± 0.93 
 
1.121 ± 0.02 
 
     F12 
 
26.24±0.42 
 
0.852 ±0.01 
 
0.939 ± 0.01 
 
13.53 ± 0.40 
 
1.140 ± 0.00 
   
  n=3*                                  
 
 
 
 
TABLE 11 : DRUG CONTENT OF PIOGLITAZONE HYDROCHLORIDE POWDER    
BLEND 
S.No 
Formulation 
Code 
Drug content 
(%) ± SD* 
 
 
1 
 
F1 
 
96.12 ± 0.00 
 
2 
 
F2 
 
97.86 ± 0.57 
 
3 
 
F3 
 
96.30 ± 0.42 
 
4 
 
F4 
 
97.15 ± 0.98 
 
5 
 
F5 
 
98.53 ± 0.52 
 
6 
 
F6 
 
96.20 ± 0.81 
 
7 
 
F7 
 
98.36 ± 0.56 
 
8 
 
F8 
 
97.48 ± 0.56 
 
9 
 
F9 
 
97.30 ± 0.66 
 
10 
 
F10 
 
98.11 ± 0.18 
 
11 
      
F11 
 
98.59 ± 0.18 
 
12 
 
F12 
 
99.88 ± 0.37 
   
n=3* 
 
 
 
 
TABLE 12: POST COMPRESSIONAL EVALUATION OF LIQUISOLID TABLETS  
Formulation 
Code 
 
General 
appearane 
Hardness 
(kg/cm2) 
Thickness 
(mm) 
Weight 
variation 
(mg) 
Friability 
(%) 
Disintegration 
time (sec) 
 
F1 
 
White colour 
 
4 
 
2.54 
 
107.45-110.12 
 
0.64 
 
6 min 12 sec 
 
F2 
 
White colour 
 
4 
 
3.20 
 
136.67-139.85 
 
0.52 
 
6 min 32 sec 
 
F3 
 
White colour 
 
5 
 
3.38 
 
157.56 – 160 
 
0.24 
 
6 min 40 sec 
 
F4 
 
White colour 
 
4 
 
2.68 
 
173.12 176.21 
 
0.41 
 
5 min 32 sec 
 
F5 
 
White colour 
 
5 
 
2.42 
 
117.28 -120.12 
 
0.52 
 
6 min 51 sec 
 
F6 
 
White colour 
 
4 
 
3.21 
 
171 -174.32 
 
0.36 
 
5 min 36 sec 
 
F7 
 
White colour 
 
4 
 
3.92 
 
223.45-225.1 
 
0.24 
 
5 min 12 sec 
 
F8 
 
White colour 
 
5 
 
4.17 
 
274.12-277.21 
 
0.29 
 
5min 35 sec 
 
F9 
 
White colour 
 
4 
 
3.85 
 
109-112.12 
 
0.64 
 
4 min 57 sec 
 
F10 
 
White colour 
 
4 
 
4.47 
 
153.12- 156.21 
 
0.47 
 
4 min 48 sec 
 
F11 
 
White colour 
 
4 
 
4.75 
 
197.21 -199.21 
 
0.30 
 
4 min 12 sec 
 
F12 
 
White colour 
 
5 
 
4.81 
 
241.21-243.47 
 
0.20 
 
3 min 48 sec 
 
n=3* 
 
 
 
 
TABLE 13: DRUG CONTENT OF PIOGLITAZONE HYDROCHLORIDE LIQUISOLID 
TABLET 
S.No 
Formulation 
code 
Drug content 
(%) ± SD* 
 
 
1 
 
F1 
 
99.12 ± 0.31 
 
2 
 
F2 
 
99.29 ± 0.25 
 
3 
 
F3 
 
99.25 ± 0.27 
 
4 
 
F4 
 
99.56 ± 0.45 
 
5 
 
F5 
 
99.45 ± 0.32 
 
6 
 
F6 
 
99.87 ± 0.54 
 
7 
 
F7 
 
99.28 ± 0.28 
 
8 
 
F8 
 
99.34 ± 0.24 
 
9 
 
F9 
 
99.24 ± 0.21 
 
10 
 
F10 
 
99.29 ± 0.54 
 
11 
      
F11 
 
99.84 ± 0.18 
 
12 
 
F12 
 
99.78 ± 0.36 
 
   n=3* 
   
 
 
 
 
 
TABLE 14a : PRECOMPRESSIONAL EVALUATION FOR DIRECTLY COMPRESSED 
TABLETS 
S.No PARAMETERS VALUES 
1 Angle of repose ± SD 24.26 ± 0.22 
2 Bulk density ± SD 0.678 ± 0.01 
3 Tapped density ± SD 0.725 ± 0.04 
4 Carr’s index ± SD 8.78 ± 0.34 
5 Hausner’s ratio ± SD 1.10 ± 0.01 
6 Drug content ± SD 98.78  ± 0.32 
 
TABLE 14b : POST COMPRESSIONAL EVALUATION FOR DIRECTLY 
COMPRESSED TABLETS 
S.No PARAMETERS VALUES 
1 Hardness  4 kg/cm2 
2 Thickness  3.25mm 
3  Diameter  8mm 
4  Weight variation 244.54 -249.49 
5 Friability  0.24 
6 Drug content ± SD 98.95 ± 0.30 
7 Disintegration time 7 min 45 sec 
 
 
 
 
 
TABLE 15a: IN VITRO RELEASE PROFILE OF PIOGLITAZONE HYDROCHLORIDE 
LIQUISOLID FORMULATION 
TIME IN  
MINUTES 
     CUMULATIVE PERCENTAGE DRUG RELEASE ± SD 
    F1   F2    F3  F4   F5 F6  
 
10 
 
10.60±1.26 
 
9.77±2.05 
 
12.48±1.91 
 
12.48±1.88 
 
12.27±1.73 
 
13.52±1.65 
 
20 
 
21.79±2.70 
 
23.99±1.48 
 
23.26±1.13 
 
24.20±1.13 
 
22.52±1.88 
 
29.00±4.65 
 
30 
 
37.26±2.85 
 
49.27±2.19 
 
53.35±1.88 
 
48.86±2.51 
 
49.90±2.36 
 
56.90±4.23 
 
40 
 
53.35±3.18 
 
67.98±1.10 
 
58.57±0.78 
 
77.91±4.82 
 
73.93±2.13 
 
71.95±5.21 
 
50 
 
78.22±3.12 
 
83.23±2.55 
 
72.99±4.03 
 
85.32±2.36 
 
83.44±3.61 
 
84.38±2.87 
 
60 
 
95.67±1.13 
 
93.79±1.56 
 
92.01±5.42 
 
93.16±0.94 
 
94.00±2.20 
 
93.27±2.55 
 
n=3* 
TABLE 15b: IN VITRO RELEASE PROFILE OF PIOGLITAZONE HYDROCHLORIDE 
LIQUISOLID FORMULATION 
TIME IN  
MINUTES 
     CUMULATIVE PERCENTAGE DRUG RELEASE ± SD 
    F7   F8    F9  F10   F11 F12 
 
10 
 
12.48±1.78 
 
13.63±0.65 
 
11.44±2.51 
 
12.79±0.72 
 
15.30±1.00 
 
18.22±1.22 
 
20 
 
29.82±2.81 
 
30.76±2.19 
 
28.69±2.91 
 
30.15±0.18 
 
34.73±1.57 
 
42.35±3.44 
 
30 
 
53.73±1.78 
 
54.46±1.91 
 
48.02±4.92 
 
51.78±1.99 
 
56.34±3.77 
 
68.46±2.66 
 
40 
 
79.42±2.91 
 
84.12±2.01 
 
76.76±4.40 
 
77.28±1.98 
 
78.06±3.13 
 
87.36±2.22 
 
50 
 
86.21±1.25 
 
87.46±1.43 
 
87.10±0.78 
 
86.68±1.26 
 
92.16±1.56 
 
95.08±0.78 
 
60 
 
95.81±1.91 
 
96.23±2.44 
 
95.36±1.95 
 
94.94±1.28 
 
97.07±1.18 
 
98.74±0.62 
 
n=3* 
 
TABLE 16 : DISSOLUTION RATE OF DRUG AFTER 10 MINUTES 
S.No 
FORMULATION 
CODE 
DISSOLUTION RATE 
AFTER 10 MINUTES 
(µg/ml) 
 
1 
 
F1 
 
100.60 
 
2 
 
F2 
 
97.70 
 
3 
 
F3 
 
120.48 
 
4 
 
F4 
 
124.82 
 
5 
 
F5 
 
127.27 
 
6 
 
F6 
 
135.24 
 
7 
 
F7 
 
120.48 
 
8 
 
F8 
 
136.34 
 
9 
 
F9 
 
114.41 
 
10 
 
F10 
 
127.91 
 
11 
 
F11 
 
153.00 
 
12 
 
F12 
 
182.27 
 
 
 
 
 
 
 
 
TABLE 17 : COMPARISON OF DISSOLUTION RATE OF PURE DRUG, 
CONVENTIONAL TABLET AND BEST FORMULATION AFTER 10 MINUTES 
  
DISSOLUTION RATE AFTER 10MINUTES(µg/ml) 
 
 
PURE DRUG 
 
41.32 
 
CONVENTIONAL TABLET 
 
95.62 
 
BEST FORMULATION 
 
182.27 
TABLE 18 : COMPARISON OF IN VITRO RELEASE PROFILE FOR 
PURE DRUG, CONVENTIONAL TABLET AND LIQUISOLID TABLET 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ±SD* 
 
 
TIME IN 
MINUTES 
 
10 
 
20 
 
30 
 
40 
 
50 
 
60 
 
 
PURE DRUG 
 
 
 
4.13±0.62 
 
 
8.63±1.0 
 
 
11.66±2.05 
 
 
15.42±4.21 
 
 
19.39±1.787 
 
 
22.00±0.82 
 
CONVENTIONAL 
TABLET 
 
 
9.56±1.57 
 
13.33±1.26 
 
17.40±1.41 
 
27.02±1.74 
 
36.84±4.09 
 
42.59±3.60 
 
LIQUISOLID 
TABLET 
 
 
18.22±1.12 
 
42.35±3.44 
 
68.46±2.66 
 
87.36±2.22 
 
95.08±0.78 
 
98.74±0.62 
 
 
 
 
 
 
TABLE: 19A IN-VITRO KINETIC RELEASE STUDIES LIQUISOLID TECHNIQUE FOR FORMULATION 
 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGHUCHI MODEL 
KORE’S MEYER 
MODEL 
HIXON CROWELL 
r2 K0(h-1) r2 K1(h-1) r2 KH(h-1/2) r2 n r2 KHC(h-1/3) 
F1 0.986 1.744 0. 7902 -0.0216 0.806 11.64 0.9944 1.2453 0.0016 0.0031 
F2 0.935 1.761 0.9454 -0.0232 0.813 13.068 0.9879 1.3090 0.0009 0.0021 
F3 0.973 1.577 0.8509 -0.0233 0.877 12.42 0.9746 1.361 0.0136 0.0083 
F4 0.955 1.759 0.9627 -0.0246 0.995 19.54 0.9765 1.2068 0.0002 0.001 
F5 0.968 1.758 0.9559 -0.0233 0.873 13.14 0.9748 1.2191 0.9802 -0.0543 
F6 0.969 1.656 0.942 -0.023 0.904 13.006 0.9858 1.1626 0.9925 -0.0516 
 
 
 
 
 
TABLE: 19B IN-VITRO KINETIC RELEASE STUDIES LIQUISOLID TECHNIQUE FOR FORMULATION 
 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGHUCHI MODEL 
KORE’S MEYER 
MODEL 
HIXON CROWELL 
r2 K0(h-1) r2 K1(h-1) r2 KH(h-1/2) r2 n r2 KHC(h-1/3) 
F7 0.971 1.7816 0.9602 -0.0248 0.892 13.393 0.987 1.2453 0.9813 -0.0578 
F8 0.9682 1.758 0.9513 -0.0269 0.911 13.326 0.9858 1.3092 0.9914 -0.0546 
F9 0.968 1.758 0.9412 -0.0267 0.895 13.587 0.987 1.1361 0.9839 0.0576 
F10 0.9697 1.659 0.9178 -0.0295 0.898 13.479 0.977 1.2068 0.9732 -0.0592 
F11 0.9698 1.722 0.9374 -0.028 0.918 13.801 0.987 1.2191 0.9861 -0.0618 
F12 0.925 1.6542 0.9737 -0.0367 0.941 14.341 0.965 1.1626 0.9959 -0.0675 
    
 
 
 
 
 TABLE 20: DISSOLUTION PROFILE OF BEST FORMULATION (F12)  AT 40OC ± 2OC AND 75% ± 5% 
TIME IN 
MINUTES 
CONTROL 
250C (Room Temperature) 400C / 75% RH 
15th day 30th day 15th day 30th day 
10 18.44±1.04 18.30±0.91 18.60±1.07 18.13±0.69 18.27±0.88 
20 42.35±1.01 41.81±0.75 42.20±1.01 41.33±0.58 42.17±0.97 
30 68.73±1.10 68.04±0.81 67.30±0.91 67.86±0.84 68.63±1.09 
40 87.52±0.82 86.65±0.82 85.52±0.81 88.39±0.48 88.31±1.09 
50 95.58±0.61 94.44±0.81 95.31±0.84 94.00±0.65 94.03±0.49 
60 98.74±0.64 98.48±1.01 97.79±0.92 97.35±0.57 97.31±0.83 
 
  
 
 
 
Figure: 5 Determination of λmax of pioglitazone hydrochloride 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 6 Calibration curve of pioglitazone hydrochloride  in phosphate 
buffer pH 7.4 
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Figure :7  Solubility of pioglitazone hydrochloride  in various non-
volatile liquid  vehicles 
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 Figure: 8a FT-IR spectrum of pioglitazone hydrochloride 
 
 
Figure: 8b  FT-IR spectrum of propylene glycol 
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 Figure: 8c FT-IR spectrum of polyethylene glycol-400 
 
 
Figure: 8d  FT-IR spectrum of tween 80 
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Figure:8e  FT-IR spectrum of microcrystalline cellulose 
 
Figure: 8f FT-IR spectrum of Aerosil 
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 Figure: 8g FT-IT spectrum of crospovidone 
 
Figure: 8h  FT-IR spectrum of Drug + Tween 80+ Microcrystalline cellulose 
+ Aerosil 
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Figure 9a:DSC thermogram of pioglitazone hydrochloride 
 
Figure 9b: DSC thermogram of liquisolid formulation 
 
 
Figure 10a: Powder X- ray diffraction studies for pioglitazone hydrochloride 
  
 
Figure 10 b : Powder X- ray diffraction studies for  liquisolid formulation 
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Figure:11   ANGLE OF REPOSE FOR ALL FORMULATIONS
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Figure :12 BULK DENSITY FOR ALL FORMULATIONS 
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Figure:13  TAPPED DENSITY FOR ALL FORMULATIONS
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Figure:14   CARR'S INDEX FOR ALL 
FORMULATIONS
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.9
0.95
1
1.05
1.1
1.15
1.2
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
H
A
U
SN
ER
'S
 R
A
TI
O
FORMULATIONS
Figure:15  HAUSNER'S RATIO FOR ALL 
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Figure:16  DRUG CONTENT FOR ALL 
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 Figure :17a in vitro release profile of liquisolid tablets of pioglitazone                                                                     
hydrochloride [MCC:SILICA(5:1)] 
 
 
Figure :17b  in vitro release profile of liquisolid tablets of pioglitazone                                                                       
hydrochloride [MCC:SILICA(10:1)] 
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 Figure : 17c in vitro release profile of liquisolid tablets of pioglitazone                                                                       
hydrochloride [MCC:SILICA(15:1)] 
 
 
Figure :17d  in vitro release profile of liquisolid tablets of pioglitazone                                                                       
hydrochloride [MCC:SILICA(20:1)] 
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Figure:18a  COMPARISON OF IN-VITRO ZERO ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING PROPYLENE GLYCOL
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Figure:18b COMPARISION OF IN-VITRO  ZERO ORDER RELEASE KINETICS OF 
FORMULATIONS CONTAINING POLYEHTYLENE GLYCOL-400
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Figure: 18c COMPARISION  OF IN -VITRO ZERO ORDER RELEASE KINETICS  
OF FORMULATIONS CONTAINING TWEEN 80
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Figure:19a COMPARISION IN-VITRO FIRST ORDER KINETICS OF 
FORMULATION CONTAINING PROPYLENE GLYCOL
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Figure:19b COMPARISION IN-VITRO FIRST ORDER RELEASE KINETICS OF 
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Figure:19c  COMPARISION IN-VITRO FIRST ORDER RELEASE KINETICS OF 
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Figure 20a: COMPARISION OF IN-VITRO HIXSON CROWELL RELEASE 
KINETICS OF FORMULATION CONTAINING PROPYLENE GLYCOL
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Figure 20b: COMPARISION OF IN-VITRO HIXSON CROWELL RELEASE 
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Figure 20c: COMPARISION OF IN-VITRO HIXSON CROWELL RELEASE 
KINETICS OF FORMULATION CONTAINING TWEEN 80
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Figure 21a: COMPARISON OF IN VITRO HIGUCHI MODEL RELEASE 
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Figure 21b: COMPARISON IN-VITRO HIGUCHI MODEL RELEASE KINETICS 
OF FORMULATION CONTAINING POLYETHYLENE GLYCOL-400
POLYEHTYLENE GLYCOL 400 1
POLYEHTYLENE GLYCOL 400 2
POLYEHTYLENE GLYCOL 400 3
POLYEHTYLENE GLYCOL 400 4
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Figure 21c :COMPARISION  OF IN-VITRO HIGUCHI MODEL RELEASE 
KINETICS OF FORMULATIONS CONTAINING TWEEN 80
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Figure 22a:COMPARISION OF IN-VITRO KORES MEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING  PROPYLENE 
GLYCOL
PROPYLENE GLYCOL 1
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Figure 22b:COMPARISION OF IN-VITRO KORES MEYER-PEPPAS 
MODEL RELEASE KINETICS OF FORMULATION CONTAINING  
POLYEHTYLENE GLYCOL-400
POLYETHYLENEGLYCOL 400 1
POLYETHYLENEGLYCOL 400 2
POLYETHYLENEGLYCOL 400 3
POLYETHYLENEGLYCOL 400 4
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Figure 22c:COMPARISION OF IN-VITRO KORES MEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING  POLYEHTYLENE 
GLYCOL-400
TWEEN 80 1
TWEEN 80 2
TWEEN 80 3
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Figure23:COMPARISION OF DISSOLUTION RATE AFTER 10 MINUTES OF 
PURE DRUG, CONVENTIONAL TABLET AND LIQUISOLID TABLET
PURE DRUG
MARKERTED TABLET
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Figure 24:COMPARISION OF IN-VITRO RELEASE STUDIES LIQUISOLID 
FORMULATION WITH PURE DRUG, AND CONVENTIONAL TABLET
PURE DRUG
MARKETED TABLET
LIQUISOLID TABLET
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Figure 25:COMPARISON OF IN-VITRO DISSOLUTION PROFILE (12) OF 0 
MONTH 1 MONTH (STORED AT  40C±2 RH 75 % ±5%)
0 month
1 month
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CHAPTER – X 
SUMMARY AND CONCLUSION 
The purpose of the study was to formulate liquisolid tablets of Pioglitazone 
hydrochloride to improve the solubility and dissolution rate. The λmax of Pioglitazone 
hydrochloride was found to be 234nm in phosphate buffer ph 7.4. The Pioglitazone 
hydrochloride obeys Beer’s law within the concentration range of 5-25 (μg/ml). The 
solubility studies were observed that the Pioglitazone hydrochloride have highest 
solubility in Tween 80 compared to other non-volatile liquid vehicles. FT-IR showed that 
there was no interaction between the drug and excipients. The DSC thermogram of 
Pioglitazone hydrochloride and liquisolid compacts, the sharpendothermic peak of pure 
drug appeared at 187oC, whereas no such peak was observed in liquisolid formulation, 
which indicates that Pioglitazone hydrochloride was molecularly dispersed and in an 
amorphous form. 
Flowable liquid retention potential (Ф-value) was used to formulate liquisolid 
tablets of Pioglitazone hydrochloride. The twelve formulations were prepared using 
different concentration of drug in liquid medication, and different ratio of microcrystalline 
cellulose & aerosil 200 and  crospovidone. The directly compressed tablets were 
prepared using microcrystalline cellulose and aerosil 200 and crospovidone, without 
addition of non-volatile liquid vehicle. 
The results of precompression studies which indicates that the prepared powder 
blend of all the formulations possess good flow properties. The postcompression 
evaluations such as hardness, thickness, weight variation, friability, drug content and 
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disintegration test of all the formulated liquisolid tablets were within the acceptable 
limits. In vitro dissolution studies of all the formulations showed immediate release of 
drug. Among 12 formulations F12 was selected as a best formulationwhich had the 
better release of drug (98.74%) and subjected to further studies. 
The in vitro release studies revealed that the liquisolid tablets showed a faster 
drug release compared to the pure drug and directly compressed tablets. The results of 
the powder X- ray diffraction studies proved that the crystallinity of pure drug was 
remarkably reduced in the best formulation.  
The dissolution rate (DR) in 10 min, increased in linear manner with increasing 
ratio of drug: Tween 80. The selected formulation showed higher release profile than 
the pure drug and directly compressed tablets. The selected formulation was found to 
be stable under the storage condition 
CONCLUSION 
 The liquisolid tablet technique can be effective way for dissolution rate 
improvement of water insoluble drugs such as Pioglitazone hydrochloride. Tween 80 
was used as a liquid vehicle. The liquid vehicle plays a contributing role in improving the 
dissolution profiles of a water insoluble drug in the liquisolid formulations, besides 
choosing a suitable liquid vehicle according to its viscosity and HLB value. Enhanced 
dissolution rates obtained in the present study in turn indicates increase in oral 
bioavailability due to increased wetting and surface area available for dissolution. Hence 
we can conclude that liquisolid tablets of paliperidone was prepared by using Tween 80 
(1:1 ratio of drug and Tween 80) and 20 ratio of microcrystalline cellulose and aerosil 
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200 provide greater release of drug (98.74 % in 60 mins) among all the formulations, 
and this ratio can be used to enhance the solubility and dissolution rate of poorly water 
soluble drug pioglitazone hydrochloride. This novel approach to the formulation may be 
helpful to improve oral bioavailability. 
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